Brian Druker, M.D., Co-inventor, Gleevec

Brian Druker M.D., Director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, JELD-WEN Chair of Leukemia Research, OHSU, and an Investigator of the Howard Hughes Medical Institute. After having trained in oncology at Harvard's Dana-Farber Cancer Institute, Dr. Druker then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and the practical application to cancer therapies. His work was instrumental in the development of Gleevec, a drug that targets the molecular defect in chronic myeloid leukemia. After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML and gastrointestinal stromal tumors. His role in the development of imatinib and its application in the clinic have resulted in numerous awards for Dr. Druker, including the John J. Kenney Award from The Leukemia and Lymphoma Society, the AACR-Richard, and many others.

George Church, Ph.D., Co-developer, Human Genome Project

George Church, Ph.D. Professor of Genetics, Harvard Medical School and Professor of Health Sciences & Technology, Harvard and MIT with Walter Gilbert. He developed the first direct genomic sequencing method in 1984 and helped initiate the Human Genome Project in 1984 while he was a Research Scientist at newly-formed Biogen Inc. He invented the broadly-applied concepts of molecular multiplexing and tags,homologous recombination methods,and DNA array synthesizers. Technology transfer of automated sequencing & software to Genome Therapeutics Corp. resulted in the first commercial genome sequence, (the human pathogen, Helicobacter pylori) in 1994. He initiated the Personal Genome Project (PGP) in 2005 and research on synthetic biology. He is director of the U.S. Department of Energy Center on Bioenergy at Harvard & MIT and director of the National Institutes of Health (NHGRI) Center of Excellence in Genomic Science at Harvard, MIT & Washington University. He has been advisor to 22 companies, most recently co-founding (with Joseph Jacobson, Jay Keasling, and Drew Endy) Codon Devices, a biotech startup dedicated to synthetic biology and (with Chris Somerville) founding LS9, which is focused on biofuels. He is a senior editor for Nature EMBO Molecular Systems Biology.

Janet Woodcock, M.D., Director, Center for Drug Evaluation & Research, FDA

Janet Woodcock is the director of the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). Dr. Woodcock has shown dedication to personalized medicine by fast-tracking individualized treatments through the FDA approval process and by encouraging collaboration between the regulatory and industry arenas. During her tenure, both of the individualized treatments Xalkori and Zelboraf received FDA approval paired with companion diagnostics. Dr. Woodcock has led many of FDA’s drug initiatives. She introduced the concept of risk management in 2000 as a new approach to drug safety. Since 2002, she has led the “Pharmaceutical Quality for the 21st Century Initiative,” FDA’s highly successful effort to modernize drug manufacturing and its regulation. In 2004, she introduced FDA’s “Critical Path” Initiative, which is designed to move medical discoveries from the laboratory to consumers more efficiently. Most recently, Dr. Woodcock launched the “Safety First” and “Safe Use” initiatives designed to improve drug safety management within and outside FDA, respectively. Dr. Woodcock previously served as FDA’s deputy commissioner and chief medical officer. She also led CDER as director from 1994–2005. Prior to joining CDER, Dr. Woodcock oversaw approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis in her position as director of the Office of Therapeutics Research and Review in FDA’s Center for Biologics Evaluation and Research. Dr. Woodcock received her medical degree from Northwestern University Medical School, and her undergraduate degree from Bucknell University. She has held teaching appointments at Pennsylvania State University and the University of California at San Francisco. She joined FDA in 1986.

Abass Alavi, M.D., Professor of Radiology, University of Pennsylvania Hospital

Abass Alavi, M.D. is one of the most respected experts in neuroimaging in the United States, particularly in the applications of PET imaging. He is Chief of the Division of Nuclear Medicine at the University of Pennsylvania’s Department of Radiology and Medical Director of PET Center at the Hospital of the University of Pennsylvania. Though full recognition of PET’s value as a molecular imaging technique came in the 1990s, Dr. Alavi has been researching PET imaging and its applications since the 1970s. Dr. Alavi has lectured at more than 300 international events. He has authored more than 600 articles published in peer-reviewed journals world-wide, 900 abstracts presented at international conferences, 150 book chapters, editorials and reviews, and 12 books on Nuclear Medicine. Dr. Alavi’s research interests focus on the clinical applications of PET imaging for the detection of cancer and other serious disorders including dementia, seizures, cardiovascular disease, and infection. In addition to his success in neuroradiology, Dr. Alavi is also the Associate Director for the Center for the Study of Aging at the Hospital of the University of Pennsylvania.

Alan F. Schatzberg, M.D., Professor, Department of Psychiatry & Behavioral Sciences, Stanford University

Alan F. Schatzberg received his M.D. from New York University. After serving in the United States Air Force, he joined the staff at McLean Hospital and the faculty of HMS. He became Clinical Director of the MMHC and Professor of Psychiatry at HMS. He moved to Stanford University to become the Kenneth T. Norris, Jr., Professor and Chairman of the Department of Psychiatry and Behavioral Sciences. He served as Chair until 2010 and now directs the Stanford Mood Disorders Center. Dr. Schatzberg has been an active investigator in the biology and psychopharmacology of depressive disorders, exploring: norepinephrine systems; glucocorticoids in psychotic major depression; and the clinical psychopharmacology and pharmocogenetics of nondelusional depression with a particular interest in chronic depression. He has authored over 600 publications and abstracts, including the Manual of Clinical Psychopharmacology. He also co-edited with Dr. Charles B. Nemeroff the Textbook of Psychopharmacology whose fourth edition appeared in 2009. He is Co-Editor-in-Chief of the Journal of Psychiatric Research and sits on many other editorial boards. He is a Past President of the American Psychiatric Association, American College of Neuropsychopharmacology and the Society of Biological Psychiatry.

Alan Mertz, President, American Clinical Laboratory Assoc. (ACLA)

Shortly after joining ACLA in 2003, Alan led ACLA’s successful campaign to eliminate the “lab services co-pay” provision in the Medicare Prescription Drug legislation. Alan also spearheaded advocacy campaigns that resulted in more than a dozen successful outcomes for laboratories, including stopping a Medicaid lab co-pay proposal in Pennsylvania, successfully challenging two competitive bidding proposals in the Florida Medicaid program, significantly restoring funding for flow cytometry services, improving components of the federal competitive bidding design, and many others. From 1998 to 2003, he served as Executive Vice President of the Healthcare Leadership Council, where he is best known for chairing the 130-member “Confidentiality Coalition” that led the successful drive to rewrite the HIPAA privacy regulations to make them workable. Alan also created the Alliance to Improve Medicare (AIM) and was a leader on such issues as liability reform, opposing the Patients’ Bill of Rights, and antitrust exemption legislation. Alan taught graduate courses for five years as an adjunct professor at George Washington University’s Graduate School in Political Management.

Allen D. Roses, M.D., CEO, Barbaresco Pharmaceuticals, Inc.

Dr. Roses was one of the first clinical neurologists to apply molecular genetic strategies to neurological diseases. His laboratory at Duke reported the chromosomal location for more than 15 diseases, including several muscular dystrophies and Lou Gehrig’s disease. He led the team that identified apolipoprotein E4 [APOE4] as the major susceptibility gene for common late-onset Alzheimer’s disease in 1992. He became Senior VP for Genetic Research at GlaxoSmithKline and a leader in applied pharmacogenetics. Dr. Roses’ GSK teams identified the first highly accurate predictive test for a drug allergy using genomic technology. A pioneer in the application of whole genome analyses for several common diseases, he returned to Duke to initiate the Deane Drug Discovery Institute. Zinfandel Pharmaceuticals, Inc. was established to design and sponsor a combination Alzheimer’s Disease diagnostic validation and clinical trial to test delay of age of onset in a pharmacogenetic-assisted clinical trial of normal individuals stratified by variable TOMM40 polyT polymorphism and age at entry. In 2012, Dr. Roses founded Barbaresco Pharmaceuticals as a target discovery company for complex diseases.

Amir Dan Rubin, President & CEO, Stanford Hospital & Clinics

Amir Dan Rubin serves as President and CEO of Stanford Hospital & Clinics in Palo Alto. He previously served as COO for the UCLA Hospital System, responsible for the operations of the Ronald Reagan UCLA Medical Center, Mattel Children's Hospital at UCLA, the Resnick Neuropsychiatric Hospital at UCLA, Santa Monica-UCLA Medical Center and Orthopedic Hospital, among others. Prior to UCLA, Amir served as COO for Stony Brook University Hospital where he was involved in efforts to improve quality, operations, and the patient experience. Prior to Stony Brook, Amir served as a VP of Operations for Memorial Hermann Hospital in Houston, and before that he was Director of Business Development for the corporate parent of the Memorial Hermann Healthcare System.

Amit Etkin, M.D., Ph.D., Investigator, Palo Alto VA & Ass. Professor of Psychiatry and Behavioral Sciences, Stanford University

Amit Etkin, MD, PhD, is an Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University, and an Investigator in the VA Sierra-Pacific Mental Illness Research Education and Clinical Center (MIRECC) at the Palo Alto VA. Dr. Etkin received his MD/PhD at Columbia University with Nobel laureate Eric Kandel, completed his psychiatry residency and concurrent postdoc at Stanford University with Alan Schatzberg, and joined the faculty at Stanford in 2009. He has been awarded the BRAINS (Biobehavioral Research Award for Innovative New Scientists) R01 Award from the National Institute of Mental Health and a Dana Neuroscience Scholar Award from the Dana Foundation, and is an Associate Editor at Neuropsychopharmacology. The overarching aim of the Etkin lab is to understand the neural basis of emotional disorders and their treatment, and to leverage this knowledge to develop novel treatment interventions.

An Pang Chieng, M.D., National PI, WARFARIN Study

An Pang Chieng, M.D. is an internal medicine specialist. He received both a B.S. in Biochemistry and Medical Doctor degree from Loma Linda University, Loma Linda, California. He began his practice with Riverside Medical Clinic, a multi-specialty specialty practice of over 100 physicians in 1991and served as the medical director from 1997 to 2003. He currently is in private practice managing the El Sereno Medical Group of 3 clinical sites, serving over 15,000 patients, mostly consisting of Hispanic and Chinese ethnic groups. Dr. Chieng has also co-founded and is the medical director of Advance Primary Care Network, an independent physician association consisting of 44 primary care physicians. Dr. Chieng has a special interest in anti-aging medicine, pharmacogenetics and the applications of genetic diagnostics in clinical practice.

Andrew Fish, Executive Director, AdvaMedDx

Andrew Fish is the first Executive Director of AdvaMedDx, the U.S. trade association representing leading manufacturers of medical diagnostic tests. AdvaMedDx was founded in 2010 as a division of AdvaMed, the medical device manufacturers association, where Mr. Fish holds the title of Senior Executive Vice President. Mr. Fish reports to the AdvaMedDx Board of Directors.Mr. Fish has extensive experience navigating the complex intersections of business, science, media, law, regulation, and politics. Earlier in Mr. Fish’s career, he served in the Senate-confirmed post of Assistant Secretary of Agriculture for Congressional and Intergovernmental Affairs. Prior to that position, he worked twice for the U.S. Senate Agriculture Committee, first as a professional staff member and later as deputy chief counsel. During law school, Mr. Fish worked in the Office of the Staff Secretary in the Clinton White House. Prior to joining AdvaMedDx, Mr. Fish was Senior Vice President of Legal and Government Affairs, General Counsel, and Secretary for the Consumer Healthcare Products Association (CHPA), representing manufacturers of non-prescription medicines. Mr. Fish also led the American Cancer Society’s federal lobbying team as the Senior Director of Federal Government Relations. Mr. Fish is a graduate of Yale University and Stanford Law School.

Andrew Kasarskis, Ph.D., Vice Chair, Dept. of Genetics & Genomic Sciences, Co-Director, Icahn Inst. for Genomics & Multiscale Biology

Dr. Kasarskis leads collaborative projects aimed at new therapeutics and diagnostics, and his research focuses on developing and applying technology to several areas including pathogen surveillance, pharmacogenomics, and the genetics of sleep. He has over a decade of experience managing research and technology development projects in software engineering, drug development, human and mouse genetics, and other biological research applications. Prior to Mount Sinai, he held positions at Pacific Biosciences, Sage Bionetworks, and Merck. Dr. Kasarskis holds a PhD in Molecular and Cellular Biology from UC Berkeley as well as a BS in Biology and a BA in Chemistry from the University of Kentucky.

Ben Jackson, Senior Director, Legal Affairs at Myriad Genetics

Ben Jackson has been with Myriad nearly eight years, from a law clerk and to his current position as Senior Director, Legal Affairs. Ben oversees Myriad’s intellectual property portfolio and much of Myriad’s commercial legal matters. He is also intimately involved in Myriad’s litigation surrounding the BRCA genes and co-authored Myriad’s amicus briefs at the Supreme Court and Federal Circuit in Prometheus v. Mayo, Akamai v. Limelight, and McKesson v. Epic Systems. Ben received a bachelor’s degree from UCLA in microbiology, immunology, and molecular genetics and his J.D. from the J. Reuben Clark Law School at Brigham Young University.

Bill McGivney, Ph.D., Principal, McGivney Global Advisors LLC

Bill McGivney is Principal, McGivney Global Advisors LLC, a consulting company advising pharma/biotech, investment houses, and informatics companies.Experience and Expertise: 1. CEO, National Comprehensive Cancer Network, NCCN (1997-2011) 2. Founder, NCCN Drugs/Biologics Compendium 3. Vice President, Coverage/Clinical Policy, Aetna (1991-1997) 4. Member, Medicare Coverage Advisory Committee (2003-2007) 5. Expanded NCCN globally in Asia, the Middle East, and Latin America 6. FDA liaison for American Medical Association (AMA) (1988-1991) 7. Directed AMA’s Technology Assessment Program, DATTA (1985-1991) 8. Ph.D. in Pharmacology, University of North Carolina Medical School; Postdoctoral Fellowship, Harvard Medical School

Brian D. Athey, Ph.D., Professor of Psychiatry and Internal Medicine University of Michigan Medical School

Brian Athey, Ph.D. is the Michael A. Savageau Collegiate Professor and Chair of the Department of Computational Medicine and Bioinformatics at the University of Michigan Medical School. He is also a Professor of Psychiatry and of Internal Medicine. He is the founding Principal Investigator of the NIH National Center for Integrative Biomedical Informatics (NCIBI), one of eight NIH National Biomedical Computing Centers. He also serves as US Academic lead and Co-PI of tranSMART, an emerging US and EU consortium to create and support an open data and analytic software “Apps Store” to accelerate clinical and translational research. Brian also serves as the Biomedical Informatics Core Director of Michigan’s Clinical and Translational Science Award (CTSA), and is Associate Director of the Michigan Institute for Clinical and Health Research (MICHR). Brian has served as Director of Academic Informatics for the Medical School. Brian is an active teacher and mentor, being the Principal Investigator of the U-M NIH/NIGMS Bioinformatics Training Grant; he has trained more than 15 Ph.D. students and Post-Doctoral Fellows.

Brook Byers, Partner, KPCB

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook was President and a Director of the Western Association of Venture Capitalists. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford’s Bio-X Advisory Council and the Stanford Eye Council. In 2007, he was awarded the “UCSF Medal” as their honorary degree equivalent. In 2008, he was elected a Fellow of the American Academy of Arts and Sciences. In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association. In May, 2010, he received an Honorary Ph.D. from Georgia Tech.

Catherine Polizzi, Ph.D., Partner, Morrison & Foerster LLP

Dr. Polizzi is a Partner at Morrison & Foerster, where she helps emerging and established companies through the challenging process of obtaining patents, providing strategic, effective portfolio counseling and management. She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including personalized medicine, cancer, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular disease, metabolic disorders, and neurodegenerative diseases such as Alzheimer's Disease. Her practice also includes due diligence evaluation and counseling in the context of venture investment assessments, as well as in connection with public and private financing, spin-offs, partnerships, and mergers and acquisitions. Dr. Polizzi is recognized as one of the Top 25 IP managers in California for three years running.

Cliff Reid, Ph.D., CEO, Complete Genomics

Clifford A. Reid, Ph.D., is co-founder of Complete Genomics and has served as President, Chief Executive Officer and Chairman since July 2005 and as a member of the board of directors since July 2005. From March 2003 to September 2005, Dr. Reid was Vice President of Collaborative Solutions at Open Text Corporation, a software company. In 1995, Dr. Reid co-founded Eloquent, Inc., a digital video communications company, and served as its Chief Executive Officer until 1999 and as its Chairman until 2003, when it was acquired by Open Text. In 1988, Dr. Reid co-founded Verity, Inc., an enterprise text search engine company, and served as its Vice President of Engineering from 1988 to 1992 and as its Executive Vice President from 1992 to 1993. Dr. Reid received a B.S. in Physics from the Massachusetts Institute of Technology, an M.B.A. from Harvard University and a Ph.D. in Management Science and Engineering from Stanford University.

David Nill, M.D., VP & CMO, Cerner

Dr. Nill is responsible for innovation of clinical aspects of health and care services for Healthe at Cerner. Healthe services include on-site clinic and pharmacy, condition management, wellness screening, and third-party administration. Additionally, Dr. Nill participates in health benefits design and integration of other. Cerner benefits into the overall approach to health which includes fitness and nutrition. Dr. Nill functions as the global corporate medical director for Cerner Corporation, working closely with their benefits team regarding health and wellbeing for associates. Dr. Nill is interested in transformation of health delivery, expanding the medical home model and improving the consumer experience. His clinical interests include sports medicine and improvement of health status, with emphasis on lifestyle change for the better for members.He received his medical degree from the University of Missouri's six-year medical program and completed his residency in Family Medicine at the Mayo Clinic.

Deneen Vojta, M.D., Senior Vice President, Business Initiatives and Clinical Affairs, UnitedHealth Group

Deneen Vojta, MD is Senior Vice President of the UnitedHealth Center for Health Reform and Modernization. As a member of the core leadership group, she supports the development of innovative new solutions to the health care challenges facing the nation. In this role, she created the partnership with the Centers for Disease Control and Prevention and the YMCA–USA, to launch the National Diabetes Prevention Program and now serves as Executive Vice President and Chief Clinical Officer of the Diabetes Prevention and Control Alliance. Dr. Vojta previously served as Vice President of Research and Innovation for UnitedHealthcare. Under her leadership, Vojta forged practical and sustainable solutions for issues confronting the health care system, including payment reform and chronic care delivery – most notably introducing a Diabetes Health Plan to the commercial marketplace. Before joining UnitedHealth, Vojta held several senior management positions in health care. Most recently, she served as CEO of MYnetico, a company she founded to focus on the child obesity epidemic facing the nation. Deneen has 15 years of executive experience in health system and health plan administration. Throughout her career she has successfully partnered with community stakeholders to improve the health care outcomes of her constituents, served as a board member of non-profit healthcare institutions, and received numerous federal and foundation grants to investigate complex health care concerns. Dr. Vojta is well published and frequently invited to speak on a number of health issues. She was educated at the University of Pittsburgh (Senior of the Year) and Temple University School of Medicine (Alpha Omega Alpha). She trained in Pediatrics at the Children’s Hospital of Philadelphia, and in 2003 she was named “Top 40 under 40” by the Philadelphia Business Journal. She lives in Edina, Minnesota, with her husband and three children.

Dennis Wall, M.D., Associate Professor, Department of Pediatrics and Division of Systems Medicine, Stanford University

Dr. Wall is Associate Professor in the Department of Pediatrics and Division of Systems Medicine at Stanford University, where his lab is developing novel approaches in systems biology to decipher the molecular pathology of autism spectrum disorder and related neurological conditions. Dr. Wall received his doctorate in Integrative Biology from the University of California, Berkeley, where he pioneered the use of fast evolving gene sequences to trace population-scale diversification across islands. Then, with a postdoctoral fellowship award from the National Science Foundation, he went on to Stanford University to address broader questions in systems biology and computational genomics, work that resulted in comprehensive functional models for both protein mutation and protein interaction. Before joining the faculty at Stanford in 2013, He spent 10 years as faculty at Harvard Medical School in Systems Biology, Pediatrics and Pathology & as Director of Computational Biology at the Center for Biomedical Informatics, where he worked to decipher the molecular pathology of autism and improve our likelihood of discovering effective, early-stage diagnostics and targets for therapeutic intervention. Dr. Wall has acted as science advisor to several biotechnology and pharmaceutical companies, has created and advised on cutting-edge approaches to cloud computing, and has received numerous awards, including the Fred R. Cagle Award for Outstanding Achievement in Biology, the Vice Chancellor's Award for Research, three awards for excellence in teaching, the Harvard Medical School Leadership award, and the Slifka/Ritvo Clinical Innovation in Autism Research Award for outstanding advancements in clinical translation.

Edgar D. Staren, M.D., Ph.D., MBA, President and CEO of CTCA Medicine and Science

Edgar D. Staren, M.D., Ph.D., MBA is a graduate of the University of Arizona. In 1982, he graduated from Loyola University Stritch School of Medicine and then received his general surgery training at Rush University Medical Center. In 1988 he completed a surgical oncology fellowship at Rush and Cook County Hospitals. Dr. Staren received his Ph.D. in tumor immunobiology and in 1999 Dr. Staren completed his MBA. Since 2005 Dr. Staren has held clinical and executive roles within Cancer Treatment Centers of America® and in July 2013, was named President and CEO of CTCA Medicine and Science.

Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing a broad spectrum of academic, industrial, patient, provider and payer communities, PMC seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. It has grown from its original 18 founding members in November 2004 to over 175 today. Previously Dr. Abrahams was Executive Director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University. Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for the House Committee on the Interior. The author of numerous essays, Dr. Abrahams serves as senior editor of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.

Eric D. Green, M.D., Ph.D., Director, National Human Genome Research Institute

Dr. Green is director of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH), a position he has held since late 2009. NHGRI is the largest organization in the world solely dedicated to genomics research. Previously, he served as the NHGRI scientific director (2002 to 2009), chief of the NHGRI Genome Technology Branch (1996 to 2009) and director of the NIH Intramural Sequencing Center (1997 to 2009). While directing an independent research program for almost two decades, Dr. Green was at the forefront of efforts to map, sequence and understand eukaryotic genomes, including significant, start-to-finish involvement in the Human Genome Project. Now, as director of NHGRI, Dr. Green is responsible for providing overall leadership of the institute's research portfolio and other initiatives. This requires significant coordination with other NIH components and funding agencies. Most recently, Dr. Green led NHGRI to the completion of a strategic planning process that yielded a new vision for the future of genomics research (“Charting a course for genomic medicine from base pairs to bedside,” Nature 2011;470:204).

Euan Ashley, Ph.D., Director, Stanford Clinical Genomics Service

Born and raised in Scotland, Euan Angus Ashley graduated with 1st class Honors in Physiology and Medicine from the University of Glasgow. He completed medical residency and a PhD in molecular cardiology at the University of Oxford before moving to Stanford University where he trained in cardiology and advanced heart failure joining the faculty in 2006. His group is focused on the application of genomics to medicine. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The paper published in the Lancet was the focus of over 300 news stories, became one of the most cited articles in clinical medicine that year, and is currently featured in the Genome Exhibition at the Smithsonian in DC. The team extended the approach in 2011 to a family of four and now routinely apply genome sequencing to the diagnosis of patients at Stanford hospital where Dr Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. Dr Ashley is a recipient of the National Innovation Award from the American Heart Association (AHA) and a National Institutes of Health (NIH) Director’s New Innovator Award. He is a Principal Investigator of the Myocardial Applied Genomics Network (MAGnet), a member of the leadership group of the AHA Council on Functional Genomics, and a member of the Institute of Medicine (IOM) of the National Academy of Sciences Roundtable on Translating Genomic-Based Research for Health. He is a peer reviewer for the NIH and the AHA as well as journals including Nature, the New England Journal of Medicine, the Lancet and the Journal of Clinical Investigation,. He is co-founder of, and advisor to, Personalis, Inc, a Menlo Park based genetic diagnostics company.

Frederick Lee, M.D., M.P.H., Director of Clinical & Translational Informatics, Oracle Health Sciences

Dr. Lee leads business development strategies in clinical & translational informatics and personalized healthcare for Oracle's Health Sciences Global Business Unit. Prior to Oracle, Fred was the Founding Executive Director & Chief Medical Officer of the P4 Medicine Institute. He also led product strategy efforts for McKesson Corporation in its Provider Technologies division and has held leadership roles in General Electric Healthcare and as a COO and Chief Medical Information Officer of a large ambulatory care network in New York. He completed an MD and residency training from Stony Brook University School of Medicine, and a Masters in Public Health from Mailman School of Public Health at Columbia.

Garret Hampton, Ph.D., Sr. Director & Head of Oncology Biomarker Dev., Research & Early Dev.(gRED) Group, Genentech

Dr. Hampton is a graduate of Trinity College Dublin, Ireland (B.A. Honors), and Imperial Cancer Research Fund / University of London received, where he received his Ph.D. in Cancer Genetics with Sir Walter Bodmer. Following a postdoctoral fellowship at the Center for Human Genome Research at the Salk Institute for Biological Studies, La Jolla, CA, Garret served as Head, Section of Human Carcinogenesis, Ludwig Institute for Cancer Research, San Diego and Assistant Professor of Medicine at University of California San Diego. Garret moved to the biopharmaceutical sector in 1997, joining Genos Biosciences as Director of Genetics; and subsequently the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, as Director of Cancer Biology Discovery and Oncology Therapeutic Area Leader. He joined Celgene Corporations’ Research Division in February 2006 as Executive Director, Molecular Medicine, and was responsible for initiating and leading the translational sciences efforts at the San Diego, San Francisco and Summit, New Jersey, Research sites. Garret most recently joined Genentech’s Research and Early Development (gRED) Group in June 2009 as Senior Director and Head of Oncology Biomarker Development. In this role, Garret is responsible for leading the Oncology Pharmacodynamic (PD), Predictive biomarker and Companion diagnostics groups and for defining and implementing the strategy for biomarker development in oncology early development.

George D. Demetri, M.D., Director of the Ludwig Center at Dana-Farber/Harvard

As director of the Center for Sarcoma and Bone Oncology and now the senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, George Demetri, MD, has long been a leader in treating complex cancers. He was a pioneer in the development of Gleevec — one of the first examples of targeted cancer therapies, focused on a form of sarcoma known as gastrointestinal stromal tumor (GIST). Subsequently, his work has led to the FDA approval of several other “smart drugs” for cancer, including Sutent for GIST and most recently Votrient for other sarcomas. He has designed and implemented a world-renowned clinical research center focused on the treatment of sarcomas, and his team is at the cutting edge of developing personalized cancer therapeutics for specific subtypes of sarcomas. Outside of the laboratory, Dr. Demetri has been instrumental in raising awareness of issues relating to sarcoma on the Internet, founding a nonprofit educational site for sarcoma patients and their families and serving as the chair of the Medical Advisory Board of the Sarcoma Foundation of America and chair of the Scientific Committee of the Hope Funds for Cancer Research.

George Sledge, JR., M.D., Professor, Division Chief, Stanford University Medical Center

Dr. George W. Sledge, Jr. is Professor of Medicine and Pathology, and Ballve-Lantero Professor of Oncology (Endowed Chair) at the Indiana University School of Medicine in Indianapolis, Indiana. Trained in Internal Medicine and Medical Oncology, he has devoted his professional career to understanding the biology and improving the treatment of breast cancer. He is co-Director of the Indiana University Simon Cancer Center’s Breast Cancer Program, and is active as both a laboratory and clinical researcher, with more than 250 scientific publications. He served as chair of the Eastern Cooperative Oncology Group’s Breast Cancer Committee (2003-2010), as a member of the Food and Drug Administration’s Oncology Drug Advisory Committee, and as a member of the Department of Defense’s Breast Cancer Research Program’s Integration Panel. He is past President of the American Society of Clinical Oncology, and currently serves on the Scientific Advisory Boards for both the Komen for the Cure Foundation and the Triple Negative Breast Cancer Foundation. He is the recipient of numerous scientific awards, including the Breast Cancer Research Foundation’s Jill Rose Award, the Komen Foundation’s Brinker Award for Scientific Distinction, and the San Antonio Breast Cancer Symposium’s William L. McGuire Award. His research interests have focused on novel biologic approaches to breast cancer therapy.

Han-Oh Park, Ph.D., CEO, Bioneer Corp.

Dr. Han-Oh Park is the founder and CEO of Bioneer Corporation, the first Korean Biotechnology company founded in 1992. Bioneer started with molecular biology products, DNA/RNA synthesis, and expanded to molecular diagnostics and RNAi therapeutics. Dr. Park co-founded the S.pombe genome knockout project resulting in the introduction of a genome-wide drug target screening system, GPScreen™. This technology will enable personalized medicine in accelerating discovery, rescuing and repurposing drugs. Dr. Park also invented SAMiRNA™, a platform showing great promise for curing incurable diseases. Dr. Park has a Ph.D. in chemistry from KAIST and B.S. in chemistry from Seoul National University.

Hanlee Ji, M.D., Medical Oncologist, Hematologist / Oncologist in Stanford University

Dr. Hanlee Ji graduated in 1994 from John Hopkins School of Medicine in Internal Medicine and went on to specialize in Oncology. He is currently the Assistant Professor, Medicine - Oncology at Stanford University CA. His research group is pursuing projects focused on personalized medicine. Specifically, he is interested in using genetic and genomic approaches in oncology to improve targeted cancer therapy, make accurate prognosis, predict cancer therapy efficacy and identify clinically relevant cancer mutations.

Howard Jacob, Ph.D., Prof., Physiology & Molecular Genetics & Chair in Genetics, Medical College of Wisconsin

Howard J. Jacob, Ph.D., Founding Director of the Personalized Medicine Program and Human and Molecular Genetics Center and Professor in Physiology and Pediatrics at the Medical College of Wisconsin and Children’s Hospital of Wisconsin. In 2010 Dr. Jacob led a team of researchers at the Medical College who for the first time ever were able to use the human genome to diagnose and treat a young boy, Nicholas Volker whose life threatening disease had baffled his doctors. Nik is now leading a fully and healthy life. Dr. Jacob completed his Ph.D. at the University of Iowa followed by fellowships at MIT, Harvard and Stanford. He has published over 230 papers. He is an entrepreneur and serves on several scientific advisory boards.

Ira Klein, M.D., MBA, Medical Director, Aetna

Ira M. Klein, M.D., MBA, FACP, Chief of Staff, Office of the Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, Inc. Dr. Klein has been with Aetna since April of 2006, and, as of September 2011, is Chief of Staff to the Chief Medical Officer, responsible for communicating and deploying the strategic efforts of the CMO in multiple areas, including leveraging of business acquisitions, and clinician and clinical program development. Before that, he operated for two years in the National Accounts Sales and Support group at the corporate level, involved in the development of new benefits designs, financial and clinical analytics for National Accounts, and the evolution of oncology strategies.

James Herman, M.D., Professor, Johns Hopkins Medical Institutions

James Herman is Professor of Oncology in The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is an attending physician at the Johns Hopkins Hospital. He has authored or co-authored more than 290 publications, among which are the most highly cited papers in the field of gene silencing. His lab studies epigenetic changes that are present in human cancer. Initial work focused on the demonstration that changes in promoter region DNA methylation can act as an alternative coding region mutation for tumor suppressor gene inactivation. Current work focuses on the use of epigenetic changes to develop treatment-selection biomarkers.

John Jay Gargus, M.D., Ph.D., Director, UCI Center for Autism Research and Translation

J. Jay Gargus received his MD-PhD in Human Genetics from Yale University School of Medicine, carried out a Residency in Pediatrics and a Fellowship in Medical Genetics, also at Yale, and is an ABMG certified medical geneticist. He joined University ofCalifornia, Irvine School of Medicine in 1992 in Human Genetics, Pediatrics and Physiology & Biophysics. His clinical subspecialty is inborn errors of metabolism, bioenergetics and membrane function, and the diagnosis of complex neurodevelopmental syndromes. Hismajor research thrust is molecular pathophysiology of the common complex polygenic diseases migraine and autism, and this work provided the foundations of the approach taken by the UCI Center for Autism Research and Translation, of which he is the Director. He has received research support for his work from the NIH, Autism Speaks, Doris Duke Foundation and The Thompson Family Foundation and is PI of industry-sponsored first-in-human clinical trials for novel molecular therapeutics.

John Niederhuber, M.D., CEO, Inova Translational Medicine Institute

Dr. Niederhuber brings a lifetime of medical knowledge, large organization management experience and vision to his position as CEO, including his most recent tenure as director of the National Cancer Institute (NCI). A nationally renowned surgeon and researcher, he has dedicated his four-decade career to the treatment and study of cancer. He has served as professor, cancer center director, National Cancer Advisory Board chair, external advisor to NCI, grant reviewer, and laboratory investigator supported by NCI and National Institutes of Health. He previously served as NCI's chief operating officer and deputy director for translational and clinical sciences and chair of the National Cancer Advisory Board (NCAB). He remains involved in research at his laboratory on the National Institutes of Health (NIH) campus. Dr. Niederhuber is a member of the Institute of Medicine of the National Academy of Science and has received numerous honors and awards.

Jose J. Haresco, Ph.D., Managing Director & Senior Equity Analyst, Medical Devices & Molecular Diagnostics, JMP Securities, LLC

Jose J. Haresco III, Ph.D. is a senior equity research analyst and Managing Director at JMP Securities. He currently leads two research verticals: Medical Devices, and Life Science Tools and Diagnostic. He joined the firm in 2010 to provide fundamental research on a variety of companies ranging from Illumina and Genomic Health to Intuitive Surgical and Boston Scientific. For almost a decade, Dr. Haresco’s research has been recognized by leading industry publications including the Wall Street Journal, Investors Business Daily, and Forbes. Prior to becoming a sell-side analyst, Dr. Haresco worked for Roche Molecular Systems and Boehringer Mannheim. Dr. Haresco holds a Ph.D. in Biological and Medical Informatics from the University of California, San Francisco, where he developed genetic algorithms for structure based drug design in the lab of Professor Emeritus Irwin “Tack” Kuntz, Ph.D. He also holds a B.S. in genetics from the University of California, Davis, and has been granted two patents involving small molecule mediated PDZ-domain inhibition.

Ken Song, M.D., Chief Executive Officer, Ariosa Diagnostics

Ken Song brought together the initial team for Ariosa Diagnostics and has served as CEO since 2009. Prior to Ariosa, Ken was an investor at Venrock and led multiple investments in healthcare companies. Ken is a board certified physician, has extensive clinical and basic science research experience, and was previously a consultant at McKinsey & Company. Ken received his B.S. in Biology from the Massachusetts Institute of Technology and his M.D. from the University of California, San Francisco.

Kevin Davies, Ph.D., Author, “The $1,000 Genome”

Kevin Davies PhD is the author of “The $1,000 Genome” and “Cracking the Genome.” He is the founding editor of Nature Genetics and the launch editor of Bio-IT World magazine. Kevin recently took up a new publishing role with the American Chemical Society. He is also collaborating with one James D. Watson on a new edition of the book “DNA”.

Kim Popovits, Chairman, CEO & President, Genomic Health

Kim Popovits has served as president and CEO of Genomic Health since 2009 and as president and chief operating officer since 2002. Prior to joining Genomic Health, Popovits served in various roles, most recently as senior vice president of marketing and sales, at Genentech, Inc. During her 15 years at Genentech, she led the successful commercialization of 14 new therapies, including Herceptin. Before joining Genentech, Popovits served as division manager for American Critical Care. In 2008, Popovits was named Woman of the Year by the Women Health Care Executives, and she has been named one of the Most Influential Women in the Bay Area by The San Francisco Business Times from 2006 to 2011. She holds a bachelor of arts in business from Michigan State University.

Leroy Hood, M.D., Ph.D., President, Institute for Systems Biology

Dr. Hood’s research has focused on fundamental biology (immunity, evolution, genomics) and on bringing engineering to biology through the development of five instruments; the DNA and protein sequencers and synthesizers and the ink-jet oligonucleotide synthesizer (making DNA arrays) for deciphering the various types of biological information (DNA, RNA, proteins and systems). These instruments constitute the technological foundation for modern molecular biology and genomics. He has applied these technologies to diverse fields including immunology, neurobiology, cancer biology, molecular evolution and systems medicine. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Dr. Hood is one of only 7 (of more than 6000 members) scientists elected to all three academies (NAS, NAE and IOM). Dr. Hood has also played a role in founding more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease and has recently cofounded the company Integrated Diagnostics—that hopefully will become a platform company for P4 medicine.

Lincoln Nadauld, M.D., Director of Cancer Genomics, Intermountain Healthcare

Dr. Lincoln Nadauld, MD/PhD, was most recently hired to head the new cancer genomics department at Intermountain Healthcare’s first in-house cancer genomic program. Dr. Nadauld attended Brigham Young University for his undergraduate degree and went on to complete medical and doctoral degrees (MD/PhD) followed by internship and residency at the University of Utah. His doctoral dissertation focused on the molecular genetics of colon cancer. He completed a fellowship in medical oncology at Stanford University where he remained as faculty at the Stanford School of Medicine focusing on cancer genomics and personalized cancer medicine. While at Stanford, he helped to develop technologies that identify DNA changes in cancer to predict whether or not a targeted cancer drug might be effective for a specific patient. Last year Dr. Nadauld was awarded the prestigious Young Investigator Award by the American Society of Clinical Oncology and the Career Development Award of the National Cancer Institute.

Maneesh Jain, Ph.D., Vice President of Marketing and Business Development, Ion Torrent, Life Technologies

Maneesh Jain joined Ion Torrent in May 2009. He brings extensive startup and marketing management experience having successfully commercialized multiple life science technologies over the past 14 years. Previously, Maneesh co-founded Auriphex, a cell sorting and analysis company. He served as interim CEO, leading up to its acquisition in 2009 by a major life science tools company. Prior to that, Maneesh held the role of senior director, Global Marketing, at Affymetrix with worldwide marketing responsibility across the company’s RNA and DNA products. Maneesh joined Affymetrix in 2005 following the acquisition of ParAllele BioScience, a company he co-founded in 2001 with researchers from Stanford University. At ParAllele, he spearheaded the company’s first product launch and successfully led strategic business alliances which resulted in the $120M acquisition by Affymetrix. In 1996, he joined the Stanford Genome Technology Center to develop novel DNA sequencing approaches and co-invented the Molecular Inversion Probe technology for highly multiplexed genetic testing. Maneesh has served as an executive consultant and advisor to several life science companies developing products and services to address unmet needs in life science research, bioinformatics, molecular diagnostics and consumer genetics. He received a Ph.D. from Stanford University and a B.S. from the California Institute of Technology where he was a Ford Scholar. He holds six pending and issued patents and has written more than 20 peer-reviewed publications in journals and books.

Michael Hunkapiller, Ph.D., President and CEO of Pacific Biosciences

Michael Hunkapiller became President & CEO of Pacific Biosciences in 2012. He is Chairman of PacBio's Board of Directors, and has served on the Board since 2005. Dr. Hunkapiller spent 21 years of his career helping build Applied Biosystems ('ABI,' now part of Life Technologies Inc.) into a market leader in the life sciences industry. From 1995 to 2004 he served as ABI's President and General Manager. In 2004 he joined Alloy Ventures as a General Partner, and in 2005 led Alloy's investment in PacBio. Dr. Hunkapiller continues to represent Alloy Ventures as a Director of NuGEN, Verinata Health and RainDance Technologies. During his term at ABI, Mike developed the R&D strategies and alliances that elevated ABI to be the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was also a founder of ABI's sister company Celera Genomics and Senior Vice President of Applera Corporation (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research.

Michael Kolodziej, M.D., National Medical Director, AETNA

Michael Kolodziej M.D. is the National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna. Dr. Kolodziej attended college and medical school at Washington University in St. Louis. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at the University Of Oklahoma School Of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011.In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He has published several manuscripts and given several presentations on cost of cancer care, oncology reimbursement reform, and use of evidence based treatment guidelines to control cost of care in oncology. Dr. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology, and they have two children, Peter (19) and Katherine (16).

Michael Shuster, Ph.D., Partner, Fenwick & West

Dr. Shuster is a partner in Fenwick & West's Intellectual Property Practice and is co-chair of the firm's Life Sciences Group. Dr. Shuster has legal and technical experience representing companies in biotechnology and high technology areas that include protein and nucleic acid chemistry, clean tech, high resolution protein structures, proteomics, genomics, combinatorial peptide libraries, vaccine development for viral and autoimmune disorders, transdermal drug delivery systems, liposomal drug formulations as well as microfluidics devices.

Mike Nohaile, Ph.D., Vice President of Strategy, Amgen

Mike Nohaile is the Vice President of Strategy at Amgen. He joined Amgen in 2012. Prior to Amgen, Mike served as the Head and General Manager of the Molecular Diagnostics Business Unit at Novartis which he founded and built from $0 to a $200 million revenue entity. Mike also served Novartis as the Head of Corporate Strategy and, before that, Head of Pharma Strategy. Prior to Novartis, he worked at McKinsey & Company where he was a partner in the New Jersey office. At McKinsey he worked extensively in the healthcare area with a particular focus on diagnostics, devices and pharmaceuticals. Mike has a Doctorate in Molecular and Cell Biology from UC Berkeley and was a Post-Doctoral Fellow at MIT in the Department of Biology.

Mike Pacanowski, Pharm.D., Associate Director, Genomics and Targeted Therapy, FDA

Dr. Pacanowski is the Associate Director for Genomics and Targeted Therapy in the Office of Clinical Pharmacology at the FDA. He is charged with helping to maximize the impact and value of individualized therapy principles in drug development and regulatory evaluation. He oversees policy, process, and scientific matters related to pharmacogenomics/targeted therapy aspects of IND, NDA, and BLA review. Dr. Pacanowski also serves as the Offices’s lead on enhancement of clinical development through use of innovative tools (e.g., biomarkers, alternative trial designs). Dr. Pacanowski received his Pharm.D. from the Philadelphia College of Pharmacy and his M.P.H. from the University of Florida. He completed a residency in Clinical Pharmacology at Bassett Healthcare in Cooperstown, NY, and a clinical research fellowship in Cardiovascular Pharmacogenomics at the University of Florida.

Randy Scott, Ph.D., Chairman and CEO, InVitae Corporation

Randy Scott, Ph.D. has served as Executive Chairman since January 2009. Prior to serving as Chairman, Randy served as Chairman and Chief Executive Officer from August 2000 through January 2009. Randy was a founder of Incyte Corporation, a genomic information company, and served Incyte in various roles, including Chairman of the Board from August 2000 to December 2001, President from January 1997 to August 2000 and Chief Scientific Officer from March 1995 to August 2000. Randy holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.

Richard A. Leach, Ph.D., Vice President, Business Development, Complete Genomics

Richard A. Leach, Ph.D. is Vice President of Business Development at Complete Genomics. Collaborating with thought leaders across the globe, his primary focus is to bring genome sequencing to broad clinical practice. Prior to Complete Genomics, he was the Vice President of Scientific Services for deCODE Genetics in Reykjavik, Iceland, while it was the world’s largest and most productive genetics research company. Joining with Shady Grove Center for Preimplantation Genetics and Integramed, he co-created advanced human embryo diagnostics for preimplantation genetic diagnostic applications. Dr. Leach founded the computational biology software company Teneo Sciences and created artificial intelligence algorithms and visualization applications to analyze large genetic datasets. Dr. Leach holds a B.S. degree in Biology from Hillsdale College, a Ph.D. in Molecular Biology from Ohio University, was a Fellow in the Division of Experimental Therapeutics at Walter Reed Army Institute of Research for the US Department of Defense.

Rina Wolf, VP Commercialization Strategies, XIFIN, Inc.

Rina Wolf, Vice President of Commercialization Strategies, Consulting & Industry Affairs, XIFIN, Inc. Ms. Wolf is a nationally recognized expert in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry, specializing in Molecular Diagnostic Laboratories. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S.. She is a former President and board member of the California Clinical Laboratory Association and is an active participant with the ACLA (American Clinical Laboratory Association) and the Personalized Medicine Coalition. Most recently Ms. Wolf held the position of Vice President of Reimbursement and Regulatory Affairs at Axial Biotech, Inc. where she was responsible for creating and implementing their successful reimbursement strategies. Prior to joining Axial Biotech, Inc. Ms Wolf held executive positions in the area of commercialization and reimbursement at RedPath Integrated Pathology, Inc., Genomic Health, Inc., and Esoterix (now LabCorp). Ms. Wolf has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.

Robert Plenge, M.D., Ph.D., VP, Head of Genetics & Pharmacogenomics, Merck Research Laboratories

Prior to Merck, Robert served as Director of Genetics and Genomics at Brigham and Women’s Hospital, Assistant Professor of Medicine at Harvard Medical School, and Associate Member of the Broad Institute of MIT and Harvard. His research focuses on genomic aspects of immune-mediated human diseases, with particular attention to rheumatoid arthritis (RA). His research has contributed to the discovery of >50 RA risk loci, with publications in the New England Journal of Medicine, Nature Genetics, amongst other top-tier journals.

Sean Tunis, M.D., President and CEO, Center for Medical Technology Policy

Sean Tunis is the director of the Center for Medical Technology Policy (CMTP). In his role, he works with leading figures from the domestic and international healthcare industry on the development of new research methods designed to maximize the effectiveness of future medical technologies. Tunis founded the CMTP in 2006 after spending five years as the chief medical officer and director of the Office of Clinical Standards and Quality for the Centers for Medicare and Medicaid Services. Tunis received his medical degree and master's degree from Stanford University and his bachelor's degree from Cornell University.

Stefan Roever, Co-founder & CEO, Genia Technologies

Stefan Roever has a broad entrepreneurial, software, and finance background. He was Co-Founder and CEO of Brokat Technologies, an encryption banking software company. Brokat reached a several billion dollar market cap and went public in 1998 on the Frankfurt Stock Exchange and on NASDAQ in 2000. Mr. Roever was honored with the Ernst and Young Entrepreneur of the Year Award in Germany. He is an active private equity investor and currently serves as Chairman of WRS Materials, a roll-up of wafer reclaim companies. Mr. Roever also is a two time award holder of Technology Pioneer by the World Economic Forum. He earned degrees in both economics and law from the University of Tuebingen.

Steve Quake, Ph.D., Professor of Bioengineering, Stanford University

Stephen Quake studied physics and mathematics at Stanford University before earning his doctorate in physics from Oxford University as a Marshall scholar. Thereafter, as a postdoc in Nobel Laureate Steven Chu's group at Stanford, he developed techniques to manipulate single DNA molecules with optical tweezers. In 1996 Steve joined the faculty of Caltech, where he was ultimately appointed Thomas and Doris Everhart Professor of Applied Physics and Physics. In 2004 he returned to Stanford to help launch a new Department of Bioengineering, where he is the Lee Otterson Professor and co-chair. Steve has received “Career” and “First” awards from the National Science Foundation and National Institutes of Health (NIH), was a Packard Fellow, was awarded an NIH Director’s Pioneer Award, and is an investigator of the Howard Hughes Medical Institute. He is a founder and scientific advisory board chair of Fluidigm, Inc. and Helicos Biosciences, Inc.

Steven H. Stein, M.D., Senior Vice President, US Clinical Development & Medical Affairs, Novartis Oncology US

Steven H. Stein, MD is Senior Vice President, US Clinical Development & Medical Affairs, at Novartis Oncology US. In this important role, Dr. Stein’s primary responsibility is leading NA Oncology medical/scientific activities, including the planning, resource allocation and execution of registration and non registration studies (Medical Affairs) clinical programs, aligned with Global and US OBU priorities. He is also responsible for the Medical Sciences & Health Outcomes function, which includes the Scientific Operations, Scientific Communications, Medical Information and Education, and Health Economics and Outcomes Research groups. Additionally, Dr. Stein provides medical support to the product planning group on the impact of line extensions, new indications and formula changes. Dr. Stein previously worked at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and also as Head of Medicines Development for Hematology and Supportive Care. He served as clinical lead for all regulatory interactions globally. Dr. Stein earned his MD from MBBCH University of Witwatersrand in Johannesburg, South Africa. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the School of Medicine, University of Pennsylvania. Dr. Stein is also an active member of several professional and scientific societies and academic committees.

Steven Rosenberg, Ph.D., Chief Scientific Officer, CardioDx

Steven Rosenberg joined CardioDx in 2006 and is responsible for the scientific staff and for research and development programs in the areas of genomics, genetics, and informatics. In addition, Steven is currently on the Board of Directors of KMT Hepatech. Prior to joining CardioDx, Steven served for three years as the Chief Scientific Officer of XDx, Inc., a molecular diagnostics company focused on the immune system. He led the group responsible for developing AlloMap, a molecular diagnostic for heart transplant patients, the first genomics-based test in transplant immunology. Prior to XDx, Steven spent a year as a consultant and visiting scholar at the University of California, Berkeley. From 1981 to 2001 he was at Chiron Corporation, where he was named one of only three Chiron Research Fellows in the company's history. He received his Ph.D. in biochemistry from the University of California, Berkeley, and is the author of more than 40 scientific publications, and an inventor of more than 20 U.S. patents.

Stuart Grieve, MB BS, BSc, DPhil(oxon), Dir. of Imaging, Charles Perkins Centre & Brain Dynamics Centre

Associate Professor Stuart Grieve MB BS, BSc, DPhil(oxon), RANZCR Sydney Medical School, University of Sydney Director of Imaging, Charles Perkins Centre & Brain Dynamics Centre. Prof Stuart Grieve is a dual-trained MRI imaging scientist and Clinical Radiologist at University of Sydney with a career focus on using imaging techniques to make a difference in healthcare. He completed his doctorate at the University of Oxford on the development of rapid imaging techniques in MRI and his medical training at the University of Sydney. His research and clinical work both focus exclusively on cardiac and neuroimaging. He heads the imaging research program at the Brain Dynamics Centre, Westmead, runs a high field preclinical MRI group at the School of Molecular Biology, and leads translational cardiac imaging groups at the Northern and Central Clinical Schools (all within the University of Sydney). He is currently reviewing Imaging Research at Sydney University and has been appointed Director of Imaging at the Charles Perkins Centre.

Suzanne D. Vernon, Ph.D., Scientific Director, CFIDS Association of America

Virologist Suzanne D. Vernon, Ph.D. has dedicated the past 15 years to solving chronic fatigue syndrome (CFS). The FDA has documented CFS as “a debilitating disease that can severely affect a patient’s day-to-day functioning and have a devastating impact on a patient’s life.Vernon led a computational and biomarker discovery team at the Centers for Disease Control and Prevention until 2007. In 5 years as scientific director of the CFIDS Association she “built” the innovative Research Institute Without Walls (RIWW). The RIWW supports and conducts top-down and bottom-up research to generate big data to generate PROs and identify disease-modifying treatments.

Vincent A. Miller, M.D., Chief Medical Officer, Foundation Medicine

Dr. Miller was appointed to serve as our Chief Medical Officer on July 31, 2013. He joined Foundation Medicine in October 2011 and served as our Senior Vice President, Clinical Development between then and July 2013. Dr. Miller previously served as an attending physician at Memorial Sloan-Kettering Cancer Center between July 1991 and October 2011. His work in clinical and translational research in lung cancer culminated in observations and collaborative efforts critical to identification of EGFR sensitizing and resistance mutations. He is considered a world’s expert in lung cancer and clinical trial design and interpretation. Dr. Miller has authored and co-authored numerous abstracts, reviews, and peer-reviewed articles, which have appeared in such journals as Proceedings of the National Academy of Science USA, Cancer Research, Clinical Cancer Research and the Journal of Clinical Oncology. Dr. Miller, a National Merit Scholar, received a BA in mathematics at the University of Pennsylvania, where he was honored as a Benjamin Franklin Scholar, and an MD at the University of Medicine and Dentistry of New Jersey in Newark. He completed an internship and residency, and then served as Chief Medical Resident in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, and subsequently a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center.

Carolyn Johnson, Anchor, ABC7 News

Most evenings, you’ll find Carolyn Johnson anchoring ABC7 News at 6 & 11 and reporting on health and science. In 2008 she celebrated 10 years with the station as an anchor and reporter; she won a regional Edward R. Murrow Award from the Radio and Television News Directors Association for best newscast; and she completed a health journalism fellowship with the California Endowment/USC Annenberg School of Communication. Carolyn brings more than 20 years of experience in television production and on-air work to her position. She began her career as an intern at KCBS-TV in Los Angeles, and then worked as a production assistant for ABC7 while still in college. She worked behind the scenes, producing numerous programs and specials at ABC7 before accepting a reporting position at KSBY-TV in San Luis Obispo. She returned to ABC7 in 1998 as a reporter and anchor. Carolyn’s industry recognitions include a 2009 Emmy Award for best evening newscast. She’s also been honored as best reporter by the American Women in Radio and Television, Golden Gate Chapter. Carolyn has won a Service to Children Award from the National Association of Broadcasters, the Eugene Block Journalism Award for Outstanding Coverage of San Francisco Human Rights Issues, the John Swett Award for Outstanding Locally Produced Education Series, the Arthritis Foundation Media Award and the Hero Award from the Neuropathy Action Foundation. She's also been recognized by RTNDA for her news reporting. Carolyn double majored in psychology and communication and graduated with honors from Stanford University.

Eric Lai, Ph.D., Senior Vice President & Head of Pharmacogenomics, Takeda

Prior to Takeda, Dr. Lai was the Senior Vice President, Research & Development, Gen-Probe, Inc. Dr. Lai previously served as Vice President, Pharmacogentics Experimental Project Coordination and Analysis, at GlaxoSmithKline (GSK). Dr. Lai was previously GSK’s Vice President, Discovery and Pipeline Genetics. Prior to joining GSK in 1995, he was an Assistant Professor in the department of Pharmacology at the University of North Carolina at Chapel Hill. Dr. Lai earned his Ph.D. in Pharmacology and Microbiology from Columbia University and B.S. in Chemistry from the University of Waterloo in Ontario, Canada.

Evian Gordon, BSc, Ph.D., MBBCh Chairman and CEO, Brain Resource

Dr. Gordon has over 20 years of experience in human brain research. He was the founding director of the Brain Dynamics Centre at Westmead Hospital, the CEO and Chairman of Brain Resource Company, and a senior lecturer in the Department of Psychological Medicine at the University of Sydney. He edited the first book on Integrative Neuroscience and has more than 250 peer-reviewed scientific publications. In 2003 he was the recipient of the inaugural Royal Societies Eureka Prize for Interdisciplinary Scientific Research.

Frederick Lee, M.D., M.P.H., Director of Clinical & Translational Informatics, Oracle Health Sciences

Dr. Lee leads business development strategies in clinical & translational informatics and personalized healthcare for Oracle's Health Sciences Global Business Unit. Prior to Oracle, Fred was the Founding Executive Director & Chief Medical Officer of the P4 Medicine Institute. He also led product strategy efforts for McKesson Corporation in its Provider Technologies division and has held leadership roles in General Electric Healthcare and as a COO and Chief Medical Information Officer of a large ambulatory care network in New York. He completed an MD and residency training from Stony Brook University School of Medicine, and a Masters in Public Health from Mailman School of Public Health at Columbia.

Gil Omenn, M.D., Ph.D., Director, University of Michigan Center for Computational Medicine & Bioinformatics

Dr. Omenn's research focuses on cancer proteomics and informatics. He leads the Proteomics Alliance for Cancer Research, the HUPO Plasma Proteome Project, the Driving Biological Problems Core of the National Center for Integrative Biomedical Informatics, and the Center for Computational Medicine and Bioinformatics. There are datasets for application of analytical tools, and there are research teams eager to engage in collaborative studies in each of these initiatives. He has long-standing interests in mechanisms of genetic predispositions to risks from environmental and occupational exposures, pharmacogenetics and pharmacogenomics, and science-based risk analyses. Gilbert Omenn is Professor of Internal Medicine, Human Genetics, and Public Health at the University of Michigan. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997-2002. He is PI of the Michigan Life Sciences Corridor Proteomics Alliance for Cancer research program and leader of the international Human Proteome Organization (HUPO)

Ira Klein, M.D., MBA, Medical Director, Aetna

Ira M. Klein, M.D., MBA, FACP, Chief of Staff, Office of the Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, Inc. Dr. Klein has been with Aetna since April of 2006, and, as of September 2011, is Chief of Staff to the Chief Medical Officer, responsible for communicating and deploying the strategic efforts of the CMO in multiple areas, including leveraging of business acquisitions, and clinician and clinical program development. Before that, he operated for two years in the National Accounts Sales and Support group at the corporate level, involved in the development of new benefits designs, financial and clinical analytics for National Accounts, and the evolution of oncology strategies.

James M. Ford, M.D., Associate Professor of Medicine and Genetics, Stanford University School of Medicine

Dr. Ford’s overall research goals are to understand the role of genetic changes in cancer genes in the risk and development of solid tumors. The laboratory focuses on how DNA repair and DNA damage response pathways are critical to tumorigenesis and are potential candidates for targeted therapeutics and prevention. A major focus is the characterization of DNA repair defects in solid tumors, and the synergistic activity of DNA damaging chemotherapy drugs and radiation with PARP inhibitors in basal-like breast cancer and GI cancers. The translation of these ideas to the clinic proceeds through clinical trials in patients with defined genetic risk for cancer. Dr. Ford also directs the Stanford Cancer Genetics Clinic, where with a team of cancer genetic counselors, patients receive genetic counseling and testing for hereditary cancer syndromes, and are offered clinical research protocols for prevention, early diagnosis and treatment of cancer in high-risk individuals. Dr. Ford has extensive experience in training and mentoring students, fellows and junior faculty members in biomedical sciences and translational research, and many former students and fellows have gone onto faculty positions at prestigious academic centers. He is the Director of the Stanford Oncology Fellowship Training Program and PI of an NCI-supported T32 training grant. In summary, Dr. Ford has a demonstrated record of successful laboratory and translational clinical research, and a track record of mentoring physician-investigators into independent academic careers.

Laurence Marton, Program Committee Chairman, PMWC

Dr. Marton serves as a consultant to industry and to nonprofit, governmental, and academic institutions. In the nonprofit sector, Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation and on the Board of Directors of Cancer Commons. In the for-profit sector, he serves on the Board of Directors of TOMA Biosciences, RenovoRx, Microsonic Systems, and Pathologica, is Chair of the Scientific Advisory Board of PharmaJet, and is on the Advisory Boards of Gem Pharmaceuticals and Silicom Ventures. Before moving from academia to industry, Dr. Marton was Dean of the University of Wisconsin Medical School and previously Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery.

Mark C. Pydynowski, Business Development, Capital One Labs

Mark leads business development at Capital One Labs, the innovation team developing new digital products in financial services. Prior to Capital One, Mark was the co-founder and CEO of SOMARK Innovations, a venture-backed life science tools company. Prior to SOMARK, Mark was a management consultant at Gallup. Mark serves on the advisory board for multiple startups that range from medical devices to digital advertising. Mark received his B.S. from Washington University in St. Louis where he studied economics and political science in addition to playing varsity baseball.

Marty Tenenbaum, Ph.D., Founder & Chairman, Cancer Commons

Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He was an Internet commerce pioneer, having founded or co-founded Enterprise Integration Technologies (1990, acquired by VeriFone), CommerceNet (1994), Veo Systems (1996, acquired by Commerce One), and Webify Solutions (2002, acquired by to IBM). He also served as an officer and Director of Medstory (acquired by Microsoft). Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves on the boards of Efficient Finance, Patients Like Me, and the Public Library of Science (PLoS). He holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

Maureen Cronin, Ph.D., Executive Director, Strategic Information Management, Celgene Corporation

Maureen Cronin is an internationally recognized biotechnology industry executive with expertise in, and passion for applied and translational science. In her former roles Dr. Cronin served as Sr. VP of Research and Product Development at Foundation Medicine where she headed efforts that launched an oncology diagnostic test based on NGS technology to sequence more than 200 cancer genes in solid tumors. Prior to that, Dr. Cronin left Genomic Health of as Vice President of Translational Research, where over nine years she built the analytical and laboratory components supporting the development, validation and launch of the Oncotype tests. Cronin’s expertise includes identifying optimal platform technologies and laboratory processes, assay integration and automation, data management, bioinformatics, and biostatistical analyses to produce high-performance, innovative, first-in-class medical products. Currently, Dr. Cronin holds the position of Executive Director of Strategic Information Management at Celgene Corporation. In this role, Dr. Cronin works directly with the Research and Early Development senior leadership, including translational development, clinical pharmacology, non-clinical development and discovery to focus on creating the computational environment necessary to conduct drug development as a data and knowledge driven enterprise. Dr. Cronin’s Ph.D. is in Molecular Pharmacology from the University of California, San Diego, and her undergraduate education from the University of California, Davis.

Melinda Richter, Founder & CEO, Prescience International, Head of Janssen Labs

Melinda Richter is the founder and CEO of Prescience International, a firm dedicated to the commercialization of science and technology through consulting on, starting and managing research centers, incubators, foundations and institutes such as the San Jose BioCenter, the San Francisco Innovation Center, the San Diego BioCenter, the Seattle BioCenter, the Environmental Business Cluster (EBC), the UC Berkeley BioExec Institute. Prescience also provides commercialization services to key government research agencies like the National Cancer Institute and the California Energy Commission; in helping get their grantees investment. The San Jose BioCenter model, a science and technology incubator that provides specialized facilities, capital equipment, laboratory support and business development services to life science and cleantech companies, has the 2009 NBIA Randall Whaley Award for Best Incubator of the Year and also the 2009 NBIA Technology Incubator of the Year Award. In that regard, the BioCenter has become the best-practice model for many entities that wish to capitalize on innovation, ranging from economic development agencies to big corporate players. Ms. Richter currently sits on the governing board of the National Business Incubation Association and the boards of University of California Berkeley’s Haas School of Business BioExec Institute and San Jose State University’s Masters of Biotechnology Program. Ms. Richter holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an M.B.A. from INSEAD in France.

Pauline Farmer-Koppenol, Associate, Fenwick & West

Pauline Farmer-Koppenol is an associate in the Intellectual Property Group of Fenwick & West LLP. Ms. Farmer's practice focuses on serving technology and life sciences clients in prosecuting patent applications, providing intellectual property strategy and counseling, and negotiating joint research agreements and patent licenses. Additionally, Ms. Farmer has analyzed patent portfolios for life science clients and investors.

Ralph Snyderman, M.D., Chancellor Emeritus, Duke University

Ralph Snyderman, MD is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine in the Duke University School of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine at Duke University from 1989 to July 2004 and led the transition of this excellent medical center into an internationally recognized leader of academic medicine. He oversaw the development of the Duke University Health System, one of the most successful integrated academic health systems in the country, and served as its first President and Chief Executive Officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery. He was amongst the first to envision and articulate the need to move the current focus of health care from the treatment of disease-events to personalized, predictive, preventive, and participatory care that is focused on the patient. Dr. Snyderman is the recipient of numerous awards recognizing his contributions to research and to developing more rationale models of health care. In 2012, he received the David E. Rogers Award from the Association of American Medical Colleges who referred to Snyderman as “the father of personalized medicine.”

Stephen Eck, M.D., Ph.D., VP & Global Head of Oncology Medical Sciences, Astellas Pharma Global Development

Stephen Eck, M.D., Ph.D, is VP and Global Head of Oncology Medical Sciences at Astellas Pharma Global Development, where he is responsible for the oversight of oncology drug development plans, much of which focuses on special cancer populations for which unique biology enables the development of personalized therapies. Dr. Eck previously served as VP Translational Medicine & Pharmacogenomics at Eli Lilly where he was responsible for the clinical pharmacology components of drug development. Prior to that, Dr. Eck served in a variety of drug development leadership roles at Pfizer. He is a Fellow of the AAAS, serves on the SAB of the ACGT Foundation and is a member of the Scientific Advisory Committee of the Fairbanks Institute.

William Wong, Ph.D., Executive Director, Cancer Commons

Dr. Wong focuses on growing Cancer Commons into a sustainable organization committed to helping patients beat cancer through precision oncology. Previously, he was General Manager and Chief Technology Officer for NetDeposit, delivering innovative streamlined payment processing solutions that empowering individuals and enterprises to manage their finances. Dr. Wong sees parallels between offering individuals access to their healthcare information and financial information online. He has also been involved in industry standards organizations and consortia, where he helped develop payment standards. Dr. Wong has also worked for Encirq Corporation, Hewlett-Packard, VeriFone and Enterprise Integration Technologies in engineering management, program management, and project management positions.

Alan H.B. Wu, Ph.D., Professor of Laboratory Medicine, UCSF Pathology & Laboratory Medicine

Dr. Wu is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital and Professor of Laboratory Medicine, University of California, San Francisco. He received B.S. degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a Ph.D. degree in analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry. Dr. Wu’s research interest has been in three areas within the field of clinical chemistry laboratory. He has been involved at the national and international levels with development and use of biochemical markers for cardiovascular disease including CK-MB, myoglobin, troponin, B-type natriuretic peptide, and markers of myocardial ischemia, and stroke. As also has a long history of analytical, clinical, and forensic toxicology. In both of these areas, Dr. Wu has co-authored the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. More recently, Dr. Wu has developed research and clinical programs in pharmacogenomics in support of the UCSF clinical pharmacogenomics laboratory. Among the areas of interest include pharmacogenomics for anticoagulants, especially warfarin, chemotherapeutics (tamoxefin, irinotecan), and drugs that can induce hypersensitivity reactions (abacavir, anticonvulsants).

Alexander (Sasha) Wait Zaranek, Ph.D., Founder & Director of Informatics, Harvard Personal Genome Project (PGP)

Sasha works on open technologies that are part of the revolution that reduced human DNA sequencing costs by a million-fold since the completion of the Human Genome Project. A current research focus is the development of Arvados -- a platform for managing and analyzing genomic and biomedical big data. The system supports clinical and research applications for processing massive data sets spanning millions of individuals across collaborating organizations, eventually encompassing exabytes of data. His contributions have led to highly cited publications in Science, Nature, the Lancet and other leading scientific journals. Sasha is also a founder of and shareholder in Clinical Future, an early stage company providing commercial support for the open-source biomedical big-data platform he designed for the PGP.

Alexander Kaplun, Ph.D., Field Application Scientist, BIOBASE

Alexander Kaplun, Ph.D. is a Field Application Scientist at BIOBASE. Dr. Kaplun’s expertise is in systematic computational analysis of high-throughput data including genomics, differential expression and gene regulation mechanisms. Dr. Kaplun received his MSc degree in Biotechnology and his PhD in Biochemistry and Molecular Biology from Ben Gurion University. He completed his postdoctoral work at Karmanos Cancer Institute, Wayne State University. He is an author and co-author of numerous peer-reviewed publications.

Ali Torkamani, Ph.D., Co-founder & CSO, Cypher Genomics

Ali Torkamani, PhD, Co-founder and CSO of Cypher Genomics, is also Director of Genome Informatics and Drug Discovery at the Scripps Translational Science Institute. Dr. Torkamani’s expertise is in the discovery and interpretation of the genetic determinants of human disease through the integration of bioinformatic strategies including machine-learning based-variant prioritization, population genetics, and systems biology.

Andre Marziali, Ph.D., Founder, Chief Scientific Officer, Boreal Genomics Inc.

A leading innovator, educator, and entrepreneur with 20 years’ experience in developing tools for life science research and technologies for nucleic acid analysis, Andre founded Boreal Genomics in 2007. Andre received his B.A.Sc. in Engineering Physics from UBC in1989, and his Ph.D. in Physics from Stanford University in 1994 where he subsequently worked for several years with Prof. Ron Davis in the Stanford DNA Sequencing Technology Center. In 1998, Andre founded the Applied Biophysics Laboratory at the University of British Columbia, the Genome BC Technology Development Platform, and in 2005 he was appointed Director of Engineering Physics at UBC.

Andy Kogelnik, M.D., Ph.D., Founder & Director, Open Medicine Institute (OMI)

Andreas Kogelnik, MD, PhD is founder and Director of OMI and a practicing physician. Prior to OMI, Dr. Kogelnik founded two companies and a non-profit organization. Having received his MD from Emory University, a PhD in Bioengineering from Georgia Tech, and completing his medical residency and fellowship at Stanford, he has been centrally involved in the information and genomic revolutions in medicine. He has served as an advisor/consultant to many Silicon Valley biotech and IT organizations including Epocrates, Counsyl, the Fogarty Institute for Innovation, and the El Camino Hospital Genomic Medicine Institute.

Ann Kapoun, Ph.D., Vice President of Translational Medicine, OncoMed Pharmaceuticals

Ann Kapoun is Vice President of Translational Medicine at OncoMed Pharmaceuticals. Her expertise is in the clinical execution and implementation of biomarkers and patient stratification approaches. Dr. Kapoun served as Associate Director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine at ALZA / Johnson & Johnson. Prior to that she was the Department Head of Biomarker R&D at Scios Inc., where she was responsible for their Biomarker and Pharmacogenomics programs in support of clinical trials. Dr. Kapoun received her Ph.D. from Indiana University, Bloomington, IN, and she has co-authored more than 30 scientific publications and patents.

Barrett Bready, Ph.D., President and CEO, Nabsys

Dr. Bready is President, CEO, and co-founder of Nabsys, a developer of semiconductor-based tools for single-molecule genomic analysis. Nabsys makes devices that look like computer chips but, in the case of the Nabsys chips, DNA molecules are read electronically as they flow through the devices. Dr. Bready has grown Nabsys from a single employee to over 50 and raised nearly $50 million in venture financing to support the company’s growth. Dr. Bready is an adjunct professor at Brown University where he teaches Biotechnology Management, a course on the business of biotechnology. He serves as a commissioner of the I-195 Redevelopment District Commission, a large land redevelopment project in downtown Providence with a focus on life sciences and other high technology sectors. He has received numerous awards, including, in 2011, Innovator of the Year. Dr. Bready received his M.D. and his Sc.B. (physics) through Brown University’s Program in Liberal Medical Education (PLME).

Catherine Ball, Ph.D., Vice President, Genomics and Bioinformatics, AncestryDNA

Catherine Ball is a genomic scientist who has annotated and mined the genomes of various organisms and created resources to help other scientists do the same. As a pioneer in data analysis resources for high-throughput biomedical technologies, Dr. Ball has used “big data” to shed light on diverse research topics, from the biology of infectious organisms to the mechanisms involved in cell division and cancer. She received a Ph.D. in Molecular Biology from UCLA and devoted several years to research in the Departments of Genetics and Biochemistry at Stanford University before establishing the genomics team at AncestryDNA.

Christina Mailloux, Ph.D., Medical Science Liaison, Iverson Genetics

Dr. Christina Mailloux serves as Medical Science Liaison for Iverson Genetics where she routinely speaks to healthcare providers about the importance and application of pharmacogenetic testing and personalized medicine. She has extensive research experience in the field of human genetics with a focus on autoimmune and inflammatory diseases. Dr. Mailloux received her B.S. degree in Biology from Tufts University and her Ph.D. in Human Medical Genetics from the University of Colorado. She completed her postdoctoral work at National Jewish Health, and previously worked at the National Institutes of Health.  

Christopher P. Leamon, Ph.D., VP Research & Development, Endocyte

Christopher P. Leamon, Ph.D., is vice president of research and development of Endocyte. Prior to joining Endocyte, Dr. Leamon conducted discovery research in the field of peptide, oligonucleotide, liposome and DNA drug delivery for GlaxoWellcome, a healthcare company, and Isis Pharmaceuticals, a biomedical pharmaceutical company. Dr. Leamon holds a B.S. in chemistry from Baldwin Wallace College and a Ph.D. in biochemistry from Purdue University.

Daniel A. Schwarz, M.D., MROC, Executive Director of R&D, Proove Biosciences

Dr. Daniel Schwarz currently serves as the Executive Director of R&D for Proove Biosciences, the leading personalized pain medicine laboratory. Dr Schwarz obtained his MD from the University of Illinois, his Surgery residency at University of Toledo; Board Certified 1994, and was a Clinical Instructor of Surgery while publishing research at University of Michigan. After a sabbatical, he returned to University of Michigan, was awarded several grants and research awards, while mentoring students and physicians. Recognizing increased narcotic abuse, he pursued his interests in addiction medicine, completing a fellowship 2007-2009; and becoming Board Certified 2010. As an MRO Certified and high-complexity laboratory director in urine toxicology, he still practices pain management and addiction/behavioral medicine with a focus on utilizing clinical pharmacogenetics to improve patient care. Previously, he was Chief Medical Advisor for Iverson Genetics, educating physicians before joining Proove Biosciences.

Daniel S. Grosu, M.D., Vice President, Clinical Development & Medical Affairs, Illumina, Inc.

Dr. Daniel Grosu joined Illumina in 2011 and is currently the Vice President of Clinical Development and Medical Affairs at the Company. He played a key role in the recent FDA clearance of the MiSeqDx, the first NGS platform to receive marketing authorization from the FDA. Dr. Grosu has a longstanding interest in innovative diagnostic technologies, spanning previous assignments with Siemens Medical Solutions, Bayer HealthCare Pharmaceuticals, and Johnson & Johnson. He holds an MD (with Distinction in Research) from Saint Louis University School of Medicine, and an MBA from the University of Oxford.

David Magnus, Ph.D., Director, Center for Biomedical Ethics at Stanford University

David Magnus, PhD is a Thomas A. Raffin Professor of Medicine and Biomedical Ethics, and as well as a Professor of Pediatrics at Stanford University, where he directs the Stanford Center for Biomedical Ethics. Dr. Magnus serves as President of the American Bioethics Program Directors, representing the leadership of 60 academic bioethics programs across North America. Dr. Magnus received his PhD in philosophy from Stanford University, and currently co-chairs Stanford Hospital and Clinics Ethics Committee. He is a member of Stanford’s End of Life Work Group, Palliative Care Board and the newly formed Innovative Care Committee. In addition, Dr. Magnus has spearheaded ethics training programs offered to medical students and clinicians. Dr. Magnus serves as Co-Editor of the American Journal of Bioethics; his published journals include Science, Hastings Center Report, Cambridge Quarterly of Healthcare Ethics, and the Journal of Law, Medicine and Ethics.

Debrah Thompson, Ph.D., Senior Fellow and Project Head of EdgeSeq, HTG Molecular Diagnostics

Debrah Thompson is a Senior Fellow and Project Head of EdgeSeq at HTG Molecular Diagnostics. Dr. Thompson did her doctoral work at the Wellcome Trust Sanger Institute as a Howard Hughes Medical Institute pre-doctoral fellow, and received her PhD from the University of Cambridge. Her work centers on adapting HTG’s patented qNPA technology to next-generation sequencing platforms to allow highly mulitplexed RNA sequencing from FFPE and other difficult-to-access tissues.

Doug Bassett, Ph.D., CSO and CTO, Ingenuity/QIAGEN

Doug Bassett is the CSO and CTO at Ingenuity Systems. Doug comes from the pharmaceutical industry and has experience in bioinformatics, molecular profiling, knowledge management and biomarker discovery applications to drug discovery and drug development. Prior to joining Ingenuity, Doug was the Site Head for Rosetta Inpharmatics at Merck. Doug has an MBA from the University of Washington, Michaell G. Foster School of Business and a PhD in Human Genetics from The Johns Hopkins University.

Evian Gordon, BSc, Ph.D., MBBCh Chairman and CEO, Brain Resource

Dr. Gordon has over 20 years of experience in human brain research. He was the founding director of the Brain Dynamics Centre at Westmead Hospital, the CEO and Chairman of Brain Resource Company, and a senior lecturer in the Department of Psychological Medicine at the University of Sydney. He edited the first book on Integrative Neuroscience and has more than 250 peer-reviewed scientific publications. In 2003 he was the recipient of the inaugural Royal Societies Eureka Prize for Interdisciplinary Scientific Research.

Frank S. Ong, M.D., Associate Director of Medical Affairs, Illumina, Inc.

Previously, Dr. Ong was a member of the faculty of Biomedical Sciences at Cedars-Sinai Medical Center in Los Angeles. He graduated from the Keck School of Medicine at the University of Southern California, then served as Resident Physician in the Department of Family Medicine at UCLA. He completed a research fellowship in genetics of blood pressure regulation in the Division of Experimental Pathology at Cedars-Sinai Medical Center and a clinical fellowship in Clinical Molecular Genetics in the Department of Pathology and Laboratory Medicine of UCLA. He has garnered numerous awards for his research in hypertension. His interest in genetics and personalized medicine has led to active participation in several population genetics consortia, focusing on the genetics of blood pressure regulation, personal genomics and pharmacogenetics.

Gavin J. Gordon, MBA, Ph.D., VP, Business Development & Strategic Alliances, CollabRx

Prior to joining CollabRx as the Head of Business Development and Alliances, Dr. Gavin J. Gordon was an Assistant Professor at Harvard Medical School and the Co-Director of the Thoracic Surgery Oncology Laboratory at Brigham and Women’s Hospital in Boston, MA. Dr. Gordon also held an academic appointment in the Dana-Farber/Harvard Cancer Center. At Harvard Medical School, Dr. Gordon directed a translational research laboratory in oncology focused on the generation, validation, and rapid commercialization of patented clinical diagnostic and predictive tests for cancer. His area of expertise is cancer-related therapies, medical devices and molecular diagnostics. Dr. Gordon has experience conducting technological and commercial due diligence, valuation, and financial modeling in the healthcare, biotech, pharmaceutical, and medical devices space. He has also consulted leading companies on strategies for systems reengineering, streamlining of operations, and maximizing profitability and revenue. Dr. Gordon holds a BA in Chemistry from the University of North Carolina, a MS in Physiology from North Carolina State University, a PhD in Molecular and Cellular Pathology from the University of North Carolina School of Medicine, and a MBA from the Franklin W. Olin Graduate School of Business at Babson College.

Gianluca Roma, MBA, Director, Product Management, WaferGen Biosystems

Gianluca began his carrier as a scientist at Gen-Probe Inc. (now Hologic) where he developed nucleic acid tests for blood screening and sexually transmitted diseases. He later joined AutoGenomics Inc. as product manager and was responsible for the infectious and genetic disease product lines on the FDA cleared INFINITI™ System. He later joined the diagnostics division at Illumina to launch the FDA cleared BeadXpress™. At Ion Torrent Gianluca held the Associate Director of Product Management position and commercialized the first next-generation targeted re-sequencing cancer panel on the Ion PGM™. He is currently the Director of Product Management at WaferGen BioSystems and holds a dual Bachelor’s degree in Arts and Biology, M.S . in Microbiology from ULM and a MBA from San Diego State University in Entrepreneurship.

Guido Baechler, President and Chief Executive Officer, Singulex

Guido Baechler was appointed as President and Chief Executive Officer of Singulex in May 2013. Mr. Baechler has worked with emerging technologies in life science and the diagnostic industry for more than two decades, including leadership positions at Roche, and, since 2010, as Senior Vice President of Operations at Singulex. Prior to 2010, Mr. Baechler served as our Vice President of Diagnostics from 2008 until 2009. From 1989 until 2008, Mr. Baechler held leadership positions at Roche Diagnostics and Roche Molecular Diagnostics, or RMD, in both Switzerland and United States, within research, development, marketing and executive management. Mr. Baechler holds a bachelor's degree in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He also completed a series of executive finance and management classes at the London School of Business and at the Haas Business School in Berkeley.

Hartmut Juhl, M.D., Founder and Chief Executive Officer, Indivumed

Hartmut Juhl attended medical school at Hamburg University, Germany and afterwards worked for 12 years in surgical oncology and cancer research. In 1998 he moved to Washington, DC (USA) and became Associate Professor for Oncology and Surgery at Georgetown University. Realizing the urgent need for high-quality biobanks and better resources to develop individualized therapies in cancer, Hartmut Juhl founded Indivumed in 2002.

James Yee, M.D., Ph.D., Chief Medical Officer and EVP, XDx

James Yee, MD, PhD, is  board certified in Internal Medicine. As Chief Medical Officer and EVP at XDx, Inc. a privately held molecular diagnostics enterprise, James has directed studies characterizing the clinical utility of novel molecular diagnostic blood tests for heart transplant recipients and other new diagnostic tests for other immune mediated conditions. Previously, James was VP and Head of Clinical and Preclinical R&D at Celera Genomics, and VP Clinical and Preclinical R&D, Roche Bioscience/ Syntex. James has expertise in the submission and approval of new therapeutic and diagnostic products in the US and internationally, scientific expertise in clinical, preclinical sciences and biotechnology platforms, FDA and international regulatory affairs.

Jeffrey Bland, Ph.D., FACN, FACB, President, Personalized Lifestyle Medicine Institute (PLMI)

Jeffrey Bland is the founder and Chairman of the Institute for Functional Medicine in 1991 that now has 100,000 physician members worldwide (www.functionalmedicine.org). I am presently the CEO of KinDex Therapeutics, a biotechnology company focused on discovering molecular solutions for metabolic disease (www.kindextherapeutics.com). My background is as a Ph.D. in clinical biochemistry as both a former academic (1971-84), and presently founder and president of the Personalized Lifestyle Medicine Institute in 2012 (www.plminstitute.org).

Jonathan Hirsch, Founder & President, Syapse

Jonathan Hirsch is the Founder and President of Syapse, a software company transforming healthcare by bringing omics into routine medical use. At Syapse, Jonathan works closely with diagnostic and healthcare providers, helping translate customer problems into software solutions. Jonathan is an Advisory Board member of the SXSW Accelerator, a mentor for UCSF Lean Launchpad for Healthcare course, and a member of the Steering Committee of Free the Data!, an effort started by Genetic Alliance to crowdsource the interpretation of cancer genes. Earlier in his career, Jonathan worked in Neuroscience Commercial Development at Abbott Laboratories, where he developed strategies to fund drug development through partnerships and private equity financing. His research at the Center for Molecular Neurobiology at the University of Chicago helped establish the effect of exercise on promoting hippocampal neurogenesis and combating Alzheimer’s disease. Jonathan received an M.Sci. in Neuroscience from Stanford University, and an A.B. in Biology and Political Philosophy from the University of Chicago.

Ken Kornman, DDS, Ph.D., Founder and CEO, Interleukin Genetics

Dr. Kornman is a Founder and Chief Executive Officer of Interleukin Genetics. He has been actively involved in genetics research on common diseases of aging for 20 years. Dr. Kornman has published more than 125 papers in scientific journals, including Science, New England Journal of Medicine, and Human Molecular Genetics, holds more than 20 patents, and retains academic appointments at Harvard University and the University of Michigan. He lectures worldwide on the transfer of technology to clinical use to improve health.

Kenneth C. Fang, M.D., Chief Medical Officer & VP, Translational Research and Clinical Development, Indi

Kenneth C. Fang, M.D., is a distinguished physician-scientist and life sciences entrepreneur with extensive industry experience in biomarker discovery and molecular diagnostics. He leads development of Indi’s programs for early detection of complex diseases, including lung cancer and Alzheimer’s disease. Prior to joining the company in late 2010, Dr. Fang was Senior Director for Clinical Development at XDx, a molecular diagnostics firm. Earlier in his career, for nearly two decades, Dr. Fang was an Assistant Professor of Medicine at the University of California at San Francisco (UCSF), where he garnered RO1 funding from the National Institutes of Health and was a Cardiovascular Research Institute (CVRI) investigator. Before joining Indi, he was a co-founder of Modus BioMedicine, where he led research and development of therapeutics and companion diagnostics to combat rejection of transplanted organs and other immune-mediated diseases. Dr. Fang received his B.A. in biochemistry and his M.D. from the University of Pennsylvania. He completed an internal medicine residency and a fellowship in pulmonary and critical care medicine at UCSF. He later completed postdoctoral research training at CVRI and is board certified in internal medicine, critical care medicine and pulmonary medicine.

Lucy Lu, SVP, Corporate and Business Development, Crescendo Bioscience Inc.

Lucy Lu is the Senior Vice President of Corporate and Business Development at Crescendo Bioscience Inc., a venture–backed molecular Dx start-up. The company focuses on autoimmune diseases test development and has launched its first product, Vectra® DA, for tracking disease activity in rheumatoid arthritis patients in 2010. Lucy joined Crescendo in the spring of 2008 and her responsibilities encompass portfolio planning, strategic partnering, license negotiation, intellectual property management, and international expansion to support the company’s growth strategy. Prior to joining Crescendo, she was Vice President, Technology Management and Head of the U.S. Chief Technology Office for Roche Diagnostics, where she built a global team focusing on life sciences, diabetes care and molecular Dx technology scouting and assessment to support corporate strategic planning and M&A. Lucy has also held various marketing, product development and R&D management positions at Applied Biosystems, Genentech and Bristol-Myers Squibb.

Mark Erlander, Ph.D., CSO, Trovagene

Mark Erlander has more than 19 years of experience directing and leading research and development for gene discovery, with a strong focus on molecular diagnostics. Prior to joining Trovagene, he was chief scientific officer at bioTheranostics, a bioMerieux company. Previously, Dr. Erlander was a group leader and research fellow at the R.W. Johnson Pharmaceutical Research Institute. He was also an assistant member and postdoctoral fellow at The Scripps Research Institute. Dr. Erlander is an accomplished researcher with 32 issued U.S. patents and 38 U.S. patent applications, and is a lead or contributing author on more than 70 scientific papers and review articles.

Martin G. Reese, Ph.D., Co-founder, President and CSO, Omicia Inc.

Dr. Martin Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Omicia, Dr. Reese served as Vice President of Discovery Informatics for ValiGen. Prior to this, Dr. Reese co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Dr. Reese developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career Dr. Reese has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Dr. Reese developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.

Michael Ball, CEO, GenoLogics

Michael Ball, the CEO for GenoLogics Life Sciences Software, has 20 years of experience in sales, marketing and business development with high growth technology companies. Michael has held VP positions at various technology companies including five years in executive management with Creo Products Inc. as VP Business Development and VP European Sales and Service. In addition, Michael was VP at Carmanah Technologies, spent seven years at Digital Equipment Corp. and has experience with several technology start-ups. Michael has a sound knowledge of mergers, acquisitions and strategic partnerships, extensive international experience and has been instrumental in repositioning GenoLogics from a single product company to a comprehensive research informatics vendor for the life sciences industry.

Michael Thaler, Professor Emeritus, UCSF

Michael Thaler is professor emeritus of pediatrics at UCSF. He holds an MD degree from the University of Toronto and an MA degree in history from UCSF. He trained in pediatrics, molecular biology and pathology, and served as Visiting Scholar in Bioethics at Stanford. He has conducted courses on social, cultural and ethical aspects of the biological sciences at UCSF, Stanford, UC Santa Cruz and UC Berkeley, and has published extensively in the scientific, clinical, and bioethics literature. His public service and professional awards include the UCSF Chancellor’s Faculty Award and the Lifetime Achievement Award of the North American Association for Pediatric Gastroenterology and Nutrition.

Mya Thomae, CEO, Myraqa

Mya has almost 20 years of experience with regulatory and quality, much of it as a consultant. Prior to becoming a consultant, Mya learned the ropes at Chiron and OraSure. Mya has been involved in numerous successful applications before FDA for clients in the US, Canada and EU. She worked with FDA to develop the special controls document and regulation for microarray devices and helped establish the precedent for parallel 510(k) submissions. Mya received a Commissioner's Special Citation at the 2009 FDA Honor Awards in recognition of her work to clear the ABI 7500 Fast Dx. Mya founded Myraqa (formerly Mya Thomae Consulting) in 2002, building on several years as an independent contractor.

Narges Bani Asadi, Ph.D., Founder & CEO, Bina Technologies

Narges Bani Asadi founded Bina to bring the results of many years of multidisciplinary research on systems biology and high performance computing at Stanford University and UC Berkeley to the world of genomics. Narges has extensive experience in informatics and high performance computing. She holds multiple patents, and has several publications including the award-winning “ParaLearn” paper at the 2010 International SuperComputing Conference. She holds a Masters and a PhD in Electrical Engineering from Stanford University.

Neil Barth, M.D., Chief Medical Officer, Agendia Inc. and Agendia NV

Dr. Neil Barth is the CMO of Agendia Inc. and Agendia NV, with nearly 35 years of experience as a pioneer in autologous stem cell transplantation, immunotherapy, and genetic biomarker development. He has 11-year tenure on the MEC, 6 years as Chief of Staff, and 2 years as Executive Medical Director for Hoag Hospital. He has authored multiple peer-reviewed journal articles, book chapters, and abstracts and is a noted speaker, facilitator, moderator and presenter. He is board certified in Internal Medicine, Hematology and Medical Oncology. He completed his M.D. at the Medical College of Ohio and Residency and Fellowship at Harbor UCLA Medical Center.

Nicholas Dracopoli, Ph.D., Vice President, Janssen R&D

Dr. Nicholas Dracopoli is Vice President, Head Oncology Biomarkers at Janssen R&D, Johnson & Johnson. In this role he is responsible for biomarker discovery, development and applications for oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Dr Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center, and as a Section Chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr Dracopoli has authored >70 scientific publications, and has extensive experience in the fields of genomics, molecular biology and cancer research.

Nikesh Kotecha, Ph.D., CEO and Co-founder, Cytobank Inc.

Dr. Nikesh Kotecha is the CEO and Co-founder of Cytobank Inc., a company focused on developing approaches focused on single cell technologies and big data. The Cytobank platform is the analysis engine behind landmark papers in signaling and the new field of mass cytometry. Dr. Kotecha received his PhD in Biomedical Informatics from Stanford University and is a consulting faculty member in the Computational and Systems Immunology program at Stanford University.

Paul Billings, M.D., Chief Medical Officer, LIFE Technologies

Dr. Paul R. Billings is the first Chief Medical Officer of LIFE Technologies, a world leader in providing nucleic acid and other analytic tools for biomedical research and the delivery of personalized medicine. Prior to joining LIFE, Dr. Billings was the founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital in Mountain View, CA. From 2007-2009, Dr. Billings served as President, Chief Executive Officer and Director of CELLective Dx Corporation, a company sought to revolutionize cancer care through the provision of microfluidic products and services focused on circulating tumor cells. For five years until 2007, he was Senior Vice President and Senior Geneticist at Laboratory Corporation of America Holdings Inc (LH).Prior to joining LH, Dr. Billings was Deputy Chief of Staff and Chief of General Internal Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. Dr. Billings graduated with an AB in History summa cum laude from UC San Diego, received both his MD and PhD degrees from Harvard University.

Paul T. Henderson, Ph.D., CEO, Accelerated Medical Diagnostics

Paul T. Henderson, PhD is the CEO of Accelerated Medical Diagnostics and Associate Adjunct Professor of Hematology & Oncology at UC Davis. Paul received his B.S. in Chemistry at the University of Florida, PhD in Organic Chemistry from the Georgia Tech and was an NIH Postdoctoral Fellow at MIT. Prior to UC Davis, Paul spent six years as a scientist at Lawrence Livermore National Laboratory developing the microdose-based diagnostics approach.

Prahalad Achutharao, Founder & CEO, InterpretOmics

Prahalad drives the overall strategy, technology and business execution for InterpretOmics. Before InterpretOmics, Prahalad was involved in setting up a niche engineering unit that manufactured key mechanical components for power generation industry. A recipient of Indian leadership award for industrial development by All India Achievers Foundation, Prahalad over the last decade was involved in core technology research, development and commercialisation in the area of High Performance, Grid and Cloud Computing. Prahalad is one of the pioneers in Integrated Genomics in India and holds two patents in the area of Grid Computing (Data Grids).

Ramesh Hariharan, Ph.D., Co-Founder and CTO, Strand Life Sciences

Ramesh Hariharan is Founder-CTO at Strand Life Sciences and Adjunct Professor at the Computer Science Department of the Indian Institute of Science. Over the last 10 years at Strand, Ramesh has led teams to build widely adopted analytical tools for high-throughput molecular profiling. Recently, Ramesh and team have been developing technology to make clinical sequencing affordable, even in self-paid settings like India. Ramesh's research contributions include several fastest known algorithms for combinatorial algorithmic problems. Ramesh received his Bachelor's degree from IIT, Delhi, his Ph.D. from the Courant Institute of Mathematical Sciences, NYU, and Post-Doc at the Max-Planck Institut fur Informatik in Saarbrucken, Germany.

Rami Zahr, NGS Field Application Specialist, IDT

Rami Zahr received his BS in Chemical Engineering from Cornell University. During the same period he researched coliform contamination in Cayuga Lake and its tributaries. After graduating, he worked at the NIH for 3 years, studying immune system development in rabbits, mice, and humans. He received his MS degree in Bioinformatics from Johns Hopkins University and is now an NGS Field Application Specialist at IDT.

Robert Farrell, J.D., Chief Financial Officer, Biovest

Robert Farrell, J.D. joined Biovest International, Inc. as CFO in December 2013. Previously, Mr. Farrell was employed by Titan Pharmaceuticals, Inc., a diversified public biotechnology company, where he served as President and CEO from 2008 to 2010, and as Executive Vice President and CFO from 1996 to 2008. From 1990 to 1996, Mr. Farrell served as Corporate Group Vice President and FO of Fresenius USA. Mr. Farrell received a J.D. from University of California, Hastings College of Law and a B.A. degree in Government and Economics with a Minor in Accounting from University of Notre Dame. Mr. Farrell is a Member of the California Bar.

Sanjay Joshi, Ph.D., CTO, Life Sciences, EMC Isilon Storage Division

Based in Seattle, his 24 year career has spanned the entire gamut of life-sciences from clinical and biotechnology research to healthcare informatics to medical devices. His current focus is Big Data in Genomics and Proteomics. Sanjay was the recipient of a $425,000 NIH Small Business Innovation Research (SBIR) grant for “proteomics processing using networked instrument routers”. He has also been a consultant on several NIH grants. He is actively involved in non-profit biotech networking and educational organizations in the Seattle area. His recent experience has included Cloud architectures for Healthcare EMR data and Life Sciences; multi-dimensional data analysis in Proteomics and Flow Cytometry; FDA and HIPAA computer systems validations; LIMS design and compliance for the genomics and biotechnology industry; translational research in embryology and imaging technologies. Sanjay received his Bachelors in Instrumentation Technology from Bangalore University with honors and Master of Biomedical Engineering from the University of New South Wales, Sydney. He also completed PhD courses in Molecular Biotechnology at the University of Washington, Seattle. Recent experience has included EMR; Proteomics and Flow Cytometry; FDA and HIPAA validations; LIMS; Translational genomics research and Imaging.

Somalee Datta, Ph.D., Director of Bioinformatics, Stanford Center for Genomics and Personalized Medicine

As the Director of Bioinformatics at SCGPM and Director of “Big Data” bioinformatics core, Somalee is responsible for development and deployment of the bioinformatics infrastructure which includes LIMS, sequencing data processing, data analysis pipelines, and a secure HPC infrastructure. Currently the bioinformatics core supports several large scale research and clinical efforts.

Steven Goodman, M.D., MHS, Ph.D., Professor of Medicine and of Health Research & Policy at Stanford University

He spent over two decades at Johns Hopkins in oncology, epidemiology and biostatistics before coming to Stanford at 2011, where he directs the Spectrum research training programs. He is vice-chair of the Methodology Committee of PCORI and scientific advisor of the Blue Cross-Blue Shield Technology Assessment program. He serves as editor of the journal Clinical Trials and senior statistical editor for the Annals of Internal Medicine. He co-directs a new Stanford center focused on studying and improving the validity of published health research.

Tamara Fraizer, Ph.D., Principal, Fish & Richardson

Dr. Fraizer began her career as an academic researcher and lecturer in population biology, with emphasis on statistics and computer modeling. She has maintained her technical interests in bioinformatics, data analysis, and software, and, as a registered patent attorney, has prosecuted patents in these areas. She has studied and is interested in open source issues. She is also following developments in personalized medicine, and has assessed and speaks on the role that intellectual property plays in developing and protecting the use of information in healthcare. Her practice emphasizes patent litigation and spans the realms of biology and information technology. She has litigated in numerous federal district courts, and has also tried cases in the US International Trade Commission and participated in reexamination at the USPTO. Dr. Fraizer holds a PhD from UC Davis in Population Biology and received her JD from Stanford Law School.

Theral Timpson, Host & Producer, Mendelspod

Theral Timpson is the host and producer of Mendelspod, where he interviews the thought leaders of the life science industry covering the latest trends and issues. He has 15 years experience establishing and growing companies in life science. Prior to Mendelspod, he founded Theral Timpson Productions, offering marketing and business development consulting. His past experience includes Vice President of Marketing at Medax International, President and Co-Founder of Consumer Genetics. Theral is an active blogger and speaker in the life science space. He received training from the E. Goldratt Institute in Theory of Constraints and holds a B.A. degree in English Literature from the University of Utah.

Title of talk: An Innovative Clinical Trial to Study the Concept of PM in Oncology

Amir Onn, M.D., Director, Center of Pulmonary Oncology, Sheba Medical Center

Dr. Onn is a graduate of the Hadassah and Hebrew University School of Medicine in Jerusalem, Israel. He completed his residency in internal medicine and fellowship in pulmonary medicine at the Tel-Aviv Sourasky Medical Center, affiliated with Tel Aviv University. He continued with post-doctoral fellowship and a clinical fellowship in interventional pulmonary oncology at the University of Texas MD Anderson Cancer Center, in Houston, Texas. He then became a member of the faculty of the Department of Pulmonary Medicine at MDACC and as an Assistant Professor received the prestigious Physician Scientist grant. Since his return to Israel in 2006, Dr. Onn has developed the Pulmonary Oncology service and became the Director of the Center of Pulmonary Oncology at Sheba Medical Center, the largest medical center in Israel. Dr. Onn is also a co-director of the Sheba Medical Center Institutional Tumor Bank, and the Program Director of the Sheba Medical Center and MDACC Sister Institution Program. He initiated the first Israeli multidisciplinary conference on lung cancer in 2011, and since then he is the chair of these annual conferences. Dr. Onn is a member of the directorate of the WIN consortium, and serves as a global coordinators for tissue procurement and processing for the WINTHER clinical trial.

Andrew Kurtz, Ph.D., Program Director, Small Business Innovation Research Development Center, NCI

Dr. Kurtz has been a Program Director in the Small Business Innovation Research Development Center at the National Cancer Institute. His management portfolio includes projects focused on early-stage cancer drug development, including small molecules, biologics, and novel multifunctional therapeutics based on nanotechnology. Previously, Dr. Kurtz was an AAAS Science and Technology Policy Fellow at the NIH, during which time he served on the management team of The Cancer Genome Atlas Pilot Project. Dr. Kurtz received a PhD in Biochemistry & Molecular Biology from The University of Texas Medical Branch at Galveston.

Bonnie Anderson, President & CEO, Veracyte, Inc.

Bonnie H. Anderson is the President and Chief Executive Officer of Veracyte. Under Ms. Anderson’s leadership, the company has achieved significant commercialization milestones since its formation as Veracyte in 2008. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She currently serves as a member of the Board of Trustees of Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a Bachelors of Science degree in Medical Technology.

Brian G. Atwood, Co-founder & Managing Director, Versant Ventures

Mr. Atwood co-founded Versant Ventures, a leading healthcare-focused venture capital firm, where he serves as a Managing Director. He also has more than 15 years of operating experience in the biotechnology industry. Prior to launching his career in venture capital, Mr. Atwood was Founder, President and Chief Executive Officer of Glycomed, a publicly traded biotechnology company. Mr. Atwood received a BS in Biological Sciences from the University of California, Irvine, an MS in Ecology from the University of California, Davis, and an MBA from Harvard Business School.

Title of talk: Host-Based Approaches to the Diagnosis and Prediction of Infectious Disease

Donna G. Crenshaw, Ph.D., MHA, Director of Strategic Partnerships, Clinical Genomics Studies, Duke University Medical Center

Donna Crenshaw, PhD, is the Director of Strategic Partnerships Clinical Genomics Studies Unit and the Center for Personalized and Precision Medicine, Department of Medicine, Duke University Medical Center. As Director of Strategic Partnerships, Donna is responsible for developing, growing, and managing corporate relationships for the Center for Personalized and Precision Medicine and the Clinical Genomics Studies Unit at Duke. These two groups, led by Dr. Geoffrey Ginsburg, undertake research, development, and clinical implementation programs in conjunction with commercial partners and academic investigators. Donna completed her PhD in Biochemistry and post-doctoral fellowship in Pharmacology and Cancer Biology at Duke University School of Medicine and went on to lecture in physiology and advanced optical microscopy. In 2000, Donna left Duke and bench science. She held positions in Business Intelligence at CuraGen Corporation and successive positions in Global Commercial Strategy, Competitor and Scientific Information, and Pharmacogenetics at GlaxoWellcome/GlaxoSmithKline. Nine years after leaving Duke, Donna returned as the Director of Strategic Initiatives for the Deane Drug Discovery Institute where she remained until joining Dr. Ginsburg’s group in 2012. Along the way, Donna also received her Masters of Healthcare Administration at the University of North Carolina at Chapel Hill.

Title of talk: Providing Centralized PM Services Support an Israeli Experience

Gad Rennert, M.D., Ph.D., Professor of Public Health, Technion & Carmel Medical Center of Clalit

Dr. Rennert is the Director of the Clalit National Cancer Control Center and head's Clalit's National Personalized Medicine Program which is a centralized professional education, training and support organ accompanied by a centralized molecular laboratory. He holds an MD degree from Ben Gurion University in Israel and a PhD degree from the School of Public Health at UNC. Dr. Rennert has published more than 200 papers in major peer reviewed journals and is mostly interested in gene-status driven treatments, prediction of cancer risk using molecular markers and gene-environment interaction in the etiology of cancer.

John Steuart, Managing Director, Prolog Ventures

John has more than 25 years of experience managing healthcare and technology venture funds and companies. Prior to Prolog, he was a co-founder and managing director of Claremont Creek Ventures. He also served as the CFO of two venture-backed public companies that were acquired by United Airlines New Ventures. He began his investment career at Alafi Capital. John earned a bachelor’s degree in economics from UC Berkeley, where he serves on the Advisory Boards for the Lester Center of Entrepreneurship and Center for Entrepreneurship and Technology.

Title of talk: Challenges in Translational Omics: Strategies for Success

Nathan Price, Ph.D., Associate Director, Institute for Systems Biology

Nathan Price is the Associate Director of the Institute for Systems Biology. He is also Affiliate Faculty in the Departments of Bioengineering and Computer Science & Engineering at the University of Washington. Prior to joining ISB in 2011, he was a faculty member at the University of Illinois at Urbana-Champaign, where he maintains adjunct appointments. Dr. Price awards include an American Cancer Society Postdoctoral Fellowship, a Howard Temin Pathway to Independence Award from the National Institutes of Health (NIH), a National Science Foundation (NSF) CAREER award, a young investigator award from the Roy J. Carver Charitable Trust, and as a Camille Dreyfus Teacher-Scholar. Dr. Price served on the National Academies-Institute of Medicine (IOM) committee to review omics based tests to predict clinical outcome in clinical trials from 2010-2012. He now serves on the Scientific Advisory Boards of the Global Genomics Group and of Trelys, Inc. He is a Deputy Editor-in-Chief of PLoS Computational Biology, an associate editor of BMC Systems Biology, Industrial Biotechnology, and Biotechnology Journal, as well as a member of the Editorial Advisory Board of Science Translational Medicine. He also serves on the Board of Directors of the P4 Medicine Institute.

Title of talk: Using DATA to Tailor Personal Treatment Decisions: The Experience of Clalit

Nicky Lieberman, M.D., Head, Community Medicine Division, Clalit Health Services, Israel

Specialized in Internal Medicine at Meir Hospital (Kfar Saba), becoming chief resident after 6 months and Deputy Director of the Hospital at the end of his fifth year of specialization. Medical Director of the Sharon-Shomron District in Clalit Medical Services. Clalit being the largest HMO in Israel and one of the largest in the world, and Sharon Shomron district being its second largest district. Held this position 1993–1998, and introduced risk management, quality assurance, and disease management in the district. Since 1998 I am Head of the Community Medical Division. Being one of the founders of the Israeli chapter of the ISPOR - in 2011 I was ellected as president of the Israeli chapter (Iternational Society for Pharmacoeconomics and outcomes research). Other fields of interest – personalized medicine (especially in oncology), Cardiology, Pharmacoeconomics, And in general, creating and implementing heath programs in the community.

Title of talk: How to Best Position Your Company for Acquisition

Noah Knauf, Managing Director, Healthcare San Francisco, Warburg Pincus

Noah Knuaf is based in San Francisco, joined Warburg Pincus in 2007 and focuses on investments in the healthcare sector. Prior to joining Warburg Pincus, Mr. Knauf worked as an investment professional at Parthenon Capital and as a consultant at Bain & Company. He received a B.S. summa cum laude in Business Administration from the University of Arizona and an M.B.A. from the Stanford Graduate School of Business, where he was an Arjay Miller scholar. Mr. Knauf is a director of Constitution Medical Investors, Home Dialysis Plus, International Technidyne Corp (ITC), Keystone Dental, PhotoThera, Silk Road Medical, and RegionalCare Hospital Partners.

Paul Conley, Ph.D., Managing Director, Paladin Capital Group

Dr. Conley leads new investments for the firm while serving as an active Director on many of Paladin’s portfolio company Boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.

Paul J. Hastings, Chairman and CEO, OncoMed Pharmaceuticals

Mr. Hastings is the Chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President, Genzyme Therapeutics Worldwide. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr. Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2010), and served on the boards of ViaCell (sold to Perkin-Elmer in 2007). He is currently Lead Director of Pacira Pharmaceuticals and on the board of Relypsa. He also serves as Chairman of the Emerging Companies Section of the Biotechnology Industry Organization, and serves on the board of the Bay Area Biosciences Association (BayBio) and the California Healthcare Institute (CHI). Mr. Hastings received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Title of talk: Mapping the Complex Drivers of Human Disease Using Protein Networks

Peter Jackson, Ph.D., Professor Stem Cell Research, Stanford University School of Medicine

Dr. Peter Jackson is Professor in the Baxter Laboratory for Stem Cell Research at Stanford, and formerly Director and Staff Scientist at Genentech. His laboratory develops cancer drug targets and pioneered proteomic network building to identify diagnostics and targets in human disease. Their discovery of new disease genes and signaling pathways in the primary cilium, a rediscovered signaling organelle, helps explain neurological and kidney disease, obesity, retinal degeneration, and cancer.

Title of talk: Personalising Health & Care Research in European Union

Sasa Jenko, Ph.D., PMP, Scientific Officer, DG for Research and Innovation Personalised Medicine Unit, European Commission

Sasa Jenko , Scientific officer at Innovative and Personalised Medicine Unit, Directorate for Health, DG Research and Innovation, European Commission. Sasa Jenko holds a Ph.D. in structural biology. She later turned to a career in science policy and management, working as a Scientific Officer at the European Commission. Her initial portfolio was in structural genomics and high-throughput technologies. Her current portfolio of projects is in epigenomics and epigenetics and she is a member of the Executive Committee of International Human Epigenome Consortium. She is involved in piloting personalised medicine in health and care systems in Europe.

Amir Onn, M.D., Director, Center of Pulmonary Oncology, Sheba Medical Center

Dr. Onn is a graduate of the Hadassah and Hebrew University School of Medicine in Jerusalem, Israel. He completed his residency in internal medicine and fellowship in pulmonary medicine at the Tel-Aviv Sourasky Medical Center, affiliated with Tel Aviv University. He continued with post-doctoral fellowship and a clinical fellowship in interventional pulmonary oncology at the University of Texas MD Anderson Cancer Center, in Houston, Texas. He then became a member of the faculty of the Department of Pulmonary Medicine at MDACC and as an Assistant Professor received the prestigious Physician Scientist grant. Since his return to Israel in 2006, Dr. Onn has developed the Pulmonary Oncology service and became the Director of the Center of Pulmonary Oncology at Sheba Medical Center, the largest medical center in Israel. Dr. Onn is also a co-director of the Sheba Medical Center Institutional Tumor Bank, and the Program Director of the Sheba Medical Center and MDACC Sister Institution Program. He initiated the first Israeli multidisciplinary conference on lung cancer in 2011, and since then he is the chair of these annual conferences. Dr. Onn is a member of the directorate of the WIN consortium, and serves as a global coordinators for tissue procurement and processing for the WINTHER clinical trial.

Cynthia Kimball, Co-founder, The Kimball Family Foundation

Cynthia Kimball is a curriculum and instruction doctoral student, hope-based consultant, facilitator, and leader. She is also a breast cancer survivor, diagnosed with the disease at 31 while living abroad in Japan. Over the next few years, two of her sisters, also in their 30s, were diagnosed with breast cancer. Eventually, she and her four siblings underwent genetic testing and were found to be carriers of the BRCA1 breast cancer gene mutation which they inherited from their father. She is a co-founder of her family's foundation, The Kimball Family Foundation, which educates on hereditary breast and ovarian cancer (HBOC).

Edgar D. Staren, M.D., Ph.D., MBA, President and CEO of CTCA Medicine and Science

Edgar D. Staren, M.D., Ph.D., MBA is a graduate of the University of Arizona. In 1982, he graduated from Loyola University Stritch School of Medicine and then received his general surgery training at Rush University Medical Center. In 1988 he completed a surgical oncology fellowship at Rush and Cook County Hospitals. Dr. Staren received his Ph.D. in tumor immunobiology and in 1999 Dr. Staren completed his MBA. Since 2005 Dr. Staren has held clinical and executive roles within Cancer Treatment Centers of America® and in July 2013, was named President and CEO of CTCA Medicine and Science.

Frank delaRama, Clinical Nurse Specialist Cancer Care Centers, Palo Alto Medical Foundation

Frank delaRama is the Prostate Cancer Nurse Navigator and Oncology/Genomics Clinical Nurse Specialist at the Palo Alto Medical Foundation. He completed his Master’s degree at UCSF School of Nursing. He continues his work with many programs and services, including Cancer Genetics, Survivorship, and studies in Cancer Treatment Decision Making Strategies. Frank blogs for Sutter Health’s MyLifeStages.org, tackling personal and family issues in prostate cancer. He serves on the Board of Directors for Breast Cancer Connections. Frank participates nationally in several oncology organizations, including the Association of Oncology Nurse Navigators, the National Coalition of Oncology Nurse Navigators, and the Oncology Nursing Certification Corporation, serving on several advisory and editorial boards.

Gabriel Eichler, Ph.D., General Manager, Client Services & Strategic Initiatives, PatientsLikeMe

Gabriel S. Eichler, PhD,is a trained bioinformatician with a career focused on health data sciences including everything from molecular pharmacology to mining personal health data. He currently leads PatientLikeMe’s work with its community of over 30,000 multiple sclerosis patients. Prior to joining PatientsLikeMe, Gabriel was the Senior Vice President ofconsulting at the Nature Publishing Group-backed startup, Relay Technology Management. He has previously spent time leading data science open innovation at InnoCentive, as a healthcare consultant at McKinsey and in Judah Folkman’s laboratory at Harvard Medical School. Gabriel took his MSc. and Phd. in Bioinformatics jointly from Boston University and the National Cancer Institute. His doctoral thesis work focused on methods of interpreting highdimensional data. His BSE is in Computer Science from the University of Pennsylvania. Gabriel has authored over 15 papers and a book chapter on cancer, personalized medicine, genomics, metabolomics and systems biology.

Jeanette McCarthy, MPH, Ph.D., Editor-in-Chief, Genome Magazine

Jeanette McCarthy, MPH, PhD, is editor-in-chief of Big Science Media’s Genome magazine, aimed at educating patients in precision medicine (launching April 2014). She is an adjunct associate professor of community and family medicine at Duke University. A UC Berkeley-trained genetic epidemiologist, Dr. McCarthy has spent her career researching the genetic underpinnings of complex traits and advancing the field of personalized medicine. Her focus is educating healthcare providers, patients, and other stakeholders in genomic and precision medicine (precisionmedicineadvisors.com). She is editor-in-chief of the Duke Center for Personalized and Precision Medicine’s website and teaches genomic and precision medicine at the University of California San Francisco.

John E. Steiner, Chief Compliance & Privacy Officer & Associate General Counsel, CTCA

John E. Steiner, Jr. is the Chief Compliance and Privacy Officer and Associate General Counsel for Cancer Treatment Centers of America (CTCA). He is responsible for the design, implementation and administration of the enterprise compliance program. Prior to CTCA, he served in a similar role for UK HealthCare of the University of Kentucky. Before that, he served as the first Chief Compliance and Privacy Officer for the Cleveland Clinic Health System. He also was Senior Counsel for the American Hospital Association. Mr. Steiner obtained his BA from the Johns Hopkins University and his JD from the Illinois Institute of Technology/ Chicago-Kent College of Law. He is a Vice-Chairman of the American Bar Association Health Law Committee.

Maayan Cohen, Co-founder & CEO, Hello Doctor

Prior to Hello Doctor, Maayan was a manager in a leading management consulting firm. She led the consumer goods and retail vertical in TASC - Israel's biggest management consulting firm (an associate of Bain & company). She specializes in consumer behavior and business strategy and published several research on e-commerce adoption.Maayan built the training program and managed the training field in NOVA - a non profit management consulting firm for non profits. Maayan holds a Bsc in Biotechnology and an MBA from Tel-aviv university.

Neil Schiffman, Patient fighting Stage 4 Lung Cancer

Neil Schiffman was diagnosed with stage IV non-small cell lung cancer in June 2011. Molecular testing showed that he has the EGFR genetic marker and T790 mutation. Mr. Schiffman’s treatments at Stanford have included Tarceva, chemotherapy, cyberknife brain surgery, and participation in a clinical trial conducted by Clovis Oncology. Since his initial diagnosis Mr. Schiffman has actively pursued helping others affected by the disease through his involvement with the Bonnie J. Addario Lung Cancer Foundation (ALCF). In November 2013 he received ALCF’s Spirit of Hope Award. Prior to his diagnosis Mr. Schiffman biked 100+ miles per week, was an Ironman triathlete and marathon runner, and had cycled across America in 30 days. Mr. Schiffman has been an educator and school administrator; for 35+ years he has been a business owner and entrepreneur. He holds a B.A. in German, Math, and Education from Boston University, and M.A. in Organization and Leadership from University of San Francisco, where he also did Advanced Graduate Study.

Ruth L. Katz, M.D., Professor of Pathology, Director of Image Analysis Lab, M.D. Anderson Cancer Center

Ruth L. Katz, M.D. is a board certified Anatomic Pathologist and Cytopathologist who is currently Professor of Pathology, Chief of Research Cytopathology, and Director, Image Cytometry Diagnostic Laboratory at The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Dr. Katz received her medical degree from the University of Witwatersrand Medical School in Johannesburg, South Africa. She completed a residency in anatomic pathology and hematopathology at the University of Cape Town, South Africa along with a residency in anatomic pathology at New England Medical Center Tufts Hospital in Boston, Massachusetts. She completed fellowships in Laboratory Medicine and Cytopathology at The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Her laboratory and research interests are in fine needle aspiration of all body sites, cytopathology of the bladder combined with special testing for molecular abnormalities by FISH and fine needle aspiration of lymphoma using a multiparameter approach. Presently her major research interest is in looking at genetic susceptibility to develop lung cancer, and she has developed a panel of novel molecular markers in sputum that are designed to predict those people at high risk for developing lung cancer. Currently she is working on developing a FISH assay to detect circulating tumor cells in lung cancer patients. She is active in numerous national and international associations including the American Society of Cytopathology, International Academy of Cytology, USCAP, and the American Association for Cancer Research. She is a well known Cytopathology lecturer and workshop leader both nationally and internationally. She has authored and co-authored over 200 articles in leading peer review journals including The New England Journal of Medicine, American Journal of Clinical Pathology, Acta Cytologica, Diagnostic Cytopathology, Cancer, Clinical Cancer Research, and Journal of the National Cancer Institute. She is listed in Top Doctors of America and is a key opinion leader in Doyen.com worldwide network of medical experts.

Sharon Terry, President and CEO, Genetic Alliance

Sharon Terry is President and CEO of the Genetic Alliance, a network transforming health by promoting openness and is founding CEO of PXE International, a research advocacy organization for the genetic condition pseudoxanthoma elasticum (PXE). Her memberships and advisories include the International Rare Disease Research Consortium and the Institute of Medicine Science and Policy Board. She was instrumental in the passage of the Genetic Information Nondiscrimination Act. Among other awards she received was the Clinical Research Forum and Foundation's Annual Award for Leadership in Public Advocacy in 2011.

Yona Barash, M.D., FACS, Surgical Oncology and General Surgery

Dr. Barash has extensive experience in the full-range of general surgery, surgical oncology, surgical endocrinology and advanced laparoscopic surgery. Experience includes esophageal, gastric, colorectal, Thyroid, parathyroid and adrenal surgery. Introduced sentinel lymph node mapping technology in the field of Melanoma and Breast cancer in our area. Genetic counseling in Breast and Colorectal Cancer.

Ysabel Duron, Founder and CEO, Latinas Contra Cancer

Ysabel Duron, Founder and CEO of Latinas Contra Cancer, based in Silicon Valley, California, has over a decade of non-profit experience. An award winning retired broadcast journalist of 43-years, in November 2013 she was named a Purpose Prize Winner by Encore.org for her second act, as a senior, who became a champion for Latinos with cancer. A cancer survivor, Duron was appointed in 2011 to the Congressionally-mandated IBCERC Committee, to investigate the state of the science on breast cancer and the environment. The 270-page report was released in February 2013. Latinas Contra Cancer, a leading advocacy and service agency, also convenes the biennial National Latino Cancer Summit. In 2009 LCC received the Health Agency Award from the Latino Caucus of the American Public Health Association.

Atul Butte, M.D., Ph.D., Division Chief, Division of Syst. Med., Dept. of Pediatrics, Stanford University & LPCH

Atul Butte, MD, PhD is Chief of the Division of Systems Medicine and Associate Professor of Pediatrics, Medicine, and by courtesy, Computer Science, at Stanford University and Lucile Packard Children's Hospital. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children's Hospital Boston, then received his PhD in Health Sciences and Technology from Harvard Medical School and MIT. Dr. Butte has authored more than 100 publications and delivered more than 120 invited presentations in personalized and systems medicine, biomedical informatics, and molecular diabetes, including 20 at the National Institutes of Health or NIH-related meetings.

Diego Miralles, M.D., Head, Janssen Research & Development and Janssen Healthcare Innovation

Dr. Diego Miralles is the management sponsor of Janssen Labs as part of his role as site head of the Janssen West Coast Research Center, part of Janssen Research & Development LLC. He oversees the business and operational management of Janssen Labs including the initial concept development, site construction, business model architecting, and company selection criteria. Miralles is also Head of Janssen Healthcare Innovation (JHI), a newly created team within Janssen R&D. JHI is actively testing and launching more than a dozen new business models. The team is focused on enhancing the value of our existing pharmaceutical business by identifying and integrating emerging technologies and novel partnerships in the following areas – clinical trials, adherence and genomics. The team is also identifying business opportunities in newly created markets such as innovative financing of healthcare, optimizing healthcare delivery and health maintenance. Miralles currently serves as an adjunct full professor in the Pharmacology department at the University of California, San Diego and is on the Board of Rady Children’s Hospital. His background includes over 13 years in the healthcare industry and 12 years in the hospital and academic worlds. Prior to heading the West Coast Research Center he was involved in the development of several drugs that made it to the market, including FTC, T-20, Prezista, Intellence and Edurant. He has extensive experience in clinical research, mostly in the HIV/AIDS space, including work on antiviral drug development at Belgium’s Tibotec BVBA, Trimeris, Inc, and Triangle Pharmaceuticals. Miralles was previously on the faculty at Duke University, Durham, NC, where he had a clinical HIV practice after serving as attending in charge at The AIDS Clinical Trial Unit, Beth Israel Medical Center, NY. He completed his fellowship in Infectious Diseases at Cornell University-New York Hospital after a residency in Internal Medicine at the Mayo Clinic in Rochester, MN. He graduated from the University Of Buenos Aires School Of Medicine in 1986.

Warren H. Hogarth, Ph.D., Partner, Sequoia Capital

Warren H. Hogarth focuses on bioinformatics, SAAS and energy companies. He is a Director of Silicon Valley Biosystems and FutureAdvisor and a Board Observer of AssureRx, C12 Energy and SunRun. Prior to joining Sequoia Capital in 2008, Warren completed his Ph.D. in Chemical Engineering from the University of Queensland in Australia, during which time he was a Fulbright Scholar at Princeton University and a Guest Scientist at the Fraunhofer Institute in Germany. In addition to his Ph.D., Warren has an M.B.A. from Harvard Business School and a B.E. and B.Comm. from the University of Queensland.

Jonathan Sheldon, Ph.D., Global Vice President Health Sciences, Oracle

Jonathan Sheldon, Ph.D., is Global Senior Director of Translational Medicine at Oracle. Previously, Dr. Sheldon was Chief Scientific Officer at InforSense, (acquired by IDBS) where he was responsible for the company's strategic direction in the life science and healthcare markets, as well as managing the technical services group responsible for customer implementations. Prior to InforSense, he was Chief Technology Officer for Confirmant Ltd, where he was responsible for developing the company's proteomics products and services. He also established the first bioinformatics group and was Head of Bioinformatics for five years at Roche Welwyn, UK. Dr. Sheldon holds a Ph.D. in Molecular Biology/Biochemistry from the University of Cambridge.